<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89D5574C-AAF7-4D96-832C-C2BA623123CE"><gtr:id>89D5574C-AAF7-4D96-832C-C2BA623123CE</gtr:id><gtr:name>Eberhard Karls University Tuebingen</gtr:name><gtr:address><gtr:line1>Wilhelmstra?e 7</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0407B94D-DABF-4B46-B5F0-2CBDC1C63C67"><gtr:id>0407B94D-DABF-4B46-B5F0-2CBDC1C63C67</gtr:id><gtr:name>national Institute on Aging</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89D5574C-AAF7-4D96-832C-C2BA623123CE"><gtr:id>89D5574C-AAF7-4D96-832C-C2BA623123CE</gtr:id><gtr:name>Eberhard Karls University Tuebingen</gtr:name><gtr:address><gtr:line1>Wilhelmstra?e 7</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0407B94D-DABF-4B46-B5F0-2CBDC1C63C67"><gtr:id>0407B94D-DABF-4B46-B5F0-2CBDC1C63C67</gtr:id><gtr:name>national Institute on Aging</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B502872D-53F9-42EB-8D1E-45D7522C3D98"><gtr:id>B502872D-53F9-42EB-8D1E-45D7522C3D98</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Wood</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G1000735"><gtr:id>626D20C7-7B2F-4DA0-A0C5-720B356298AF</gtr:id><gtr:title>A systematic investigation into the pathogenesis and course of Parkinson's syndrome</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G1000735</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>In this ambitious proposal we have assembled a group of world-leading clinical and basic science researchers possessing complementary expertise to identify and tackle the causes of Parkinsons Disease (PD). The overall goal will be a fuller understanding of the molecular pathogenesis of PD as well as improved clinical assessment of the disease prodrome. The main goals of the project are:|1. To undertake comprehensive genetic analysis of a large number of well characterised PD patients to identify rare variants and novel genes that cause and predispose to disease.|2. To perform state of the art molecular and biochemical characterisation of existing and novel PD-causing gene products and their pathways to delineate the regulation and function of these proteins.|3. To clinically dissect the prodrome of PD using a large series of at risk patients.|The consortium brings together both established PD researchers and senior researchers from other disciplines whose expertise brings new skills to this programme.||This research should yield crucial new knowledge of the molecular pathways leading to neurodegeneration and shed insight into the causation of PD|</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1984270</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute on Aging</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>International Parkinson's disease consortium</gtr:description><gtr:id>34238998-4753-4038-B81E-0031F0D7ED75</gtr:id><gtr:impact>Publication in Nature genetics and Hum Mol genetics and a further recent submission</gtr:impact><gtr:outcomeId>NRumZQXz5gQ-1</gtr:outcomeId><gtr:partnerContribution>Building international consortium</gtr:partnerContribution><gtr:piContribution>Principal UK contributor</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eberhard Karls University of Tubingen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Neurogenetics</gtr:department><gtr:description>International Parkinson's disease consortium</gtr:description><gtr:id>0FE5EEA3-8A95-46FA-86A8-401C53938318</gtr:id><gtr:impact>Publication in Nature genetics and Hum Mol genetics and a further recent submission</gtr:impact><gtr:outcomeId>NRumZQXz5gQ-2</gtr:outcomeId><gtr:partnerContribution>Building international consortium</gtr:partnerContribution><gtr:piContribution>Principal UK contributor</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GlaxoSmithKline (GSK)</gtr:description><gtr:id>1BAC252A-D22A-44B9-BBAB-39A6F1FC20CA</gtr:id><gtr:impact>MRI scanning of LRRK2 mutation carriers. Development of improved highly selective LRRK2 inhibitors. Helped characterise the most selective LRRK2 inhibitor described to date.</gtr:impact><gtr:outcomeId>CPC9MricGjU-1</gtr:outcomeId><gtr:partnerContribution>MRI scanning of LRRK2 mutation carriers. Development of improved highly selective LRRK2 inhibitors. Helped characterise the most selective LRRK2 inhibitor described to date.</gtr:partnerContribution><gtr:piContribution>MRI scanning of LRRK2 mutation carriers. Development of improved highly selective LRRK2 inhibitors. Helped characterise the most selective LRRK2 inhibitor described to date.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Janssen Pharmaceuticals</gtr:department><gtr:description>Janssen Pharmaceutica</gtr:description><gtr:id>8DF4AB32-073A-4C28-A550-16F7E8D8AAC5</gtr:id><gtr:impact>Helped Janssen Pharmaceutica develop an ELISA-based assay to readily assess the impact of LRRK2 inhibitors on cells and tissues by monitoring the impact that these have on LRRK2 phosphorylation of Ser910 and Ser935 (Delbroek et al. 2013) using highly selective monoclonal antibodies we developed against these residues (Dzamko et al. 2012).</gtr:impact><gtr:outcomeId>56e04350a8cd92.87808575-1</gtr:outcomeId><gtr:partnerContribution>Helped Janssen Pharmaceutica develop an ELISA-based assay to readily assess the impact of LRRK2 inhibitors on cells and tissues by monitoring the impact that these have on LRRK2 phosphorylation of Ser910 and Ser935 (Delbroek et al. 2013) using highly selective monoclonal antibodies we developed against these residues (Dzamko et al. 2012).</gtr:partnerContribution><gtr:piContribution>Helped Janssen Pharmaceutica develop an ELISA-based assay to readily assess the impact of LRRK2 inhibitors on cells and tissues by monitoring the impact that these have on LRRK2 phosphorylation of Ser910 and Ser935 (Delbroek et al. 2013) using highly selective monoclonal antibodies we developed against these residues (Dzamko et al. 2012).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Neurobiological insights into alpha synuclein</gtr:description><gtr:id>853A386D-26A0-48A8-8975-199FD6D863CA</gtr:id><gtr:impact>Neurobiological insights into alpha synuclein. Developed single molecule FRET to allow above studies to be undertaken. Original article in Cell 2012 Cremades et al (PMID: 22632969)</gtr:impact><gtr:outcomeId>G1h55A5a6Nu-1</gtr:outcomeId><gtr:partnerContribution>Neurobiological insights into alpha synuclein. Developed single molecule FRET to allow above studies to be undertaken. Original article in Cell 2012 Cremades et al (PMID: 22632969)</gtr:partnerContribution><gtr:piContribution>Neurobiological insights into alpha synuclein. Developed single molecule FRET to allow above studies to be undertaken. Original article in Cell 2012 Cremades et al (PMID: 22632969)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Biogen Idec</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C793F4CB-F58C-4B0C-B11D-170A96E59418</gtr:id><gtr:impact>John Hardy gave a seminar on the genetics of Parkinson's Disease at biotechnology company Biogen Idec in Cambridge, Massachusetts in July 2013. Teleconference and WebEx were used in the presentation, which increased the audience to thousands.</gtr:impact><gtr:outcomeId>56e14e448f4f39.83553070</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parkinson's UK Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>664A5781-43AD-4BD3-9031-ED4FD9620044</gtr:id><gtr:impact>Details on the finding of 5 genes which are involved in Parkinson's disease

Picked up for UK press release</gtr:impact><gtr:outcomeId>pwDeMfuWAYp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TREM2 talk in Rome</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F88A1340-C994-4708-ACFB-C8A529555F49</gtr:id><gtr:impact>Talk to specialists on themes raised in recent editorial in the New England Journal at a Marguerite RoAD Investigator Meeting</gtr:impact><gtr:outcomeId>56e156161b8cf7.37477654</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Broomfield Hospital, Chelmsford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B8343587-6E52-48D4-899B-AB715D5F7423</gtr:id><gtr:impact>Talk on the genetics of Parkinson's Disease and Alzheimer's Disease given to medical students on 25th April 2014.</gtr:impact><gtr:outcomeId>56e1558e3c0d76.92399133</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Genetics of LRRK2 (webcast)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E1131113-CC5A-43CC-A4F5-E77AF974FBBF</gtr:id><gtr:impact>http://www.ucl.ac.uk/ukpdc/news-publications/video-lrrk2-genetics-nick-wood

Providing insight into ongoing neurodegenerative disease research to lay people.</gtr:impact><gtr:outcomeId>B5R238knFoL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>XXXIV Nordic Congress in Clinical Chemistry</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>51B38804-6BC8-4D79-9C47-612AF4409F2F</gtr:id><gtr:impact>International conference held in Gothenburg, Sweden from 16th-19th September 2014. Talk: &amp;quot;Next generation sequencing in clinical diagnosis&amp;quot;.</gtr:impact><gtr:outcomeId>56e1552094a564.41415722</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at Hebrew University-Hadassah Medical School</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>24D26D61-4C7A-4C52-86CA-B98747197306</gtr:id><gtr:impact>Talk given by John Hardy on the genetic analysis of neurodegeneration to staff and students at the Hebrew University-Hadassah Medical School in Jerusalem in September 2013.</gtr:impact><gtr:outcomeId>56e14f1c7678d6.94175449</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Telegraph Article</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0AD6275E-D544-4A0D-927C-B0DC38DC416F</gtr:id><gtr:impact>Press release of the findings of genetic studies of Parkinson's disease

Increased interest from general public on PD genetic research</gtr:impact><gtr:outcomeId>DWEiqNVTp1j</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release of 'Genetic mutations linked to Parkinson's disease' article</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>83A120F2-D62F-4B45-9CA1-6BDC311EE31F</gtr:id><gtr:impact>Press release of consortium study, published in Nature Neuroscience, showing how how genetic mutations linked to Parkinson's disease might play a key role in the death of brain cells, potentially paving the way for the development of more effective drug treatments.

News articles in Daily Mail, Herald Scotland, The Australian, and Huffington Post:

http://www.dailymail.co.uk/health/article-2389706/Parkinsons-disease-caused-genetic-defect-claim-scientists-believe-closer-treating-condition.html
http://www.heraldscotland.com/news/health/new-hope-for-brain-disease-treatment.21835795
http://www.theaustralian.com.au/news/latest-news/cell-clue-to-parkinsons-treatment/story-fn3dxix6-1226695592048
http://www.huffingtonpost.co.uk/2013/08/12/cell-targeting-treatment-parkinsons-disease_n_3742248.html



Public and media interest, increased exposure.</gtr:impact><gtr:outcomeId>sy3x2AKY2ss</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/ukpdc/news-publications/genetic-mutation-parkinsons-disease-link-fbxo7</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Video: Advances in Genetic Understanding of Parkinson's Disease</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>85875521-50AD-4CDE-A54F-FEBE30884722</gtr:id><gtr:impact>Webcast of the presentation entitled 'Advances in Genetic Understanding of Parkinson's Disease' given by Nicholas Wood (University College London, United Kingdom) presented at the Biochemical Society Hot Topic event, PINK1-Parkin Signalling in Parkinson's Disease and Beyond, held in December 2014. Video published on 8th January 2015.

Too early to tell at date of form submission.</gtr:impact><gtr:outcomeId>54b923c7348e93.63224565</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=sXg36yrMnc8</gtr:url><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuromedia Corner</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9EDE2159-6CCD-48F5-930C-BDA8F8AFFEE3</gtr:id><gtr:impact>Interviewed for a webcast explaining the recent advances in the genetics of Parkinson's Disease. 


unknown</gtr:impact><gtr:outcomeId>S41ZPSnb7pi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PUK site visit - 2013</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FD934C45-43BD-4378-B7D3-98658557F917</gtr:id><gtr:impact>Site visits from the public and special interest groups to provide insight into how research is being done on Parkinson's disease.

Hosted by Andrey Abramov.

--</gtr:impact><gtr:outcomeId>VunFvsahddy</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Media Centre Expert Encounter</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>33395F36-469D-4A28-86F2-E4F917D6871E</gtr:id><gtr:impact>This engagement activity was in the style of an informal press briefing, on the topic &amp;quot;Should boxing be banned?&amp;quot; John Hardy was the sole member of the panel. This took place at The Wellcome Trust offices on 25th February 2013.</gtr:impact><gtr:outcomeId>56e15778ec0b94.77651082</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Material World live interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CCFAC4D2-8F01-42CB-BC99-16028814772A</gtr:id><gtr:impact>John Hardy was interviewed live for BBC Radio 4's Material World with Quentin Cooper. This reached audiences throughout the UK and beyond. The broadcast took place on 4th April 2013.</gtr:impact><gtr:outcomeId>56e15740de9579.19483738</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Organisation Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>ED3A3BE4-3B05-4F6E-B785-67153F23E4E4</gtr:id><gtr:impact>Site visits from the public and special interest groups to provide insight into how research is being done on Parkinson's disease.

 Mark Cooper has hosted annual site visits from A level Biology students to learn about Parkinson's disease.</gtr:impact><gtr:outcomeId>56e158543724e0.73421151</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture on the autophagy signaling network</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>184A3EDE-EDF0-4067-8F2D-FA08103C45FA</gtr:id><gtr:impact>Public lecture by Francesco Cecconi, an eminent scientist in the field of autophagy and neurodegeneration, on Thursday the 25th of April 2013.</gtr:impact><gtr:outcomeId>56e1596b945986.09384838</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/ukpdc/news-publications/public-lecture-london-authophagy-francesco-cecconi</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKPDC website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C1679D32-9C07-4EC1-9714-7875B7123630</gtr:id><gtr:impact>Website providing an overview of UKPDC researchers, and their collaborators, what they do, and their research output - along with news updates on activities and published papers.

www.ucl.ac.uk/ukpdc

Public interest, wide reach.</gtr:impact><gtr:outcomeId>p9BKuB5PqGA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Mary Lyon Centre, MRC Harwell</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CAC38202-9DB1-4571-914E-260718BD8ABD</gtr:id><gtr:impact>Talk given by Prof John Hardy to research staff at MRC Harwell Mammalian Genetics Unit on the Harwell Science and Innovation Campus in Oxfordshire on 11th February 2014. Title: &amp;quot;Genetic analysis of neurodegenerative disease: towards the endgame&amp;quot;.</gtr:impact><gtr:outcomeId>56e1500bec7795.90079441</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Biochemical Society meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7A8A87B0-3246-4195-BAB9-2F468D39B0FA</gtr:id><gtr:impact>Invited by the Biochemical Society to speak. Talk entitled &amp;quot;Unravelling the role of defective genes&amp;quot;; given at the conference &amp;quot;Beyond GWAS - a Biochemical Society meeting/workshop&amp;quot; on 1st July 2014 in London.</gtr:impact><gtr:outcomeId>56e15553843db6.76355691</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parkinson's UK Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DD71DDA9-2FEC-4340-B6F1-E31EBDBA96D8</gtr:id><gtr:impact>Information disseminated to the general public about how changes in PINK1 can lead to Parkinson's disease

Interest from PD society member visits to lab about the work that is being undertaken</gtr:impact><gtr:outcomeId>CibfhdwuxBi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Audioslide presentation of a paper by Claudia Manzoni on how LRRK2 PD patient cells react to starvation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4CF84D12-675B-4739-AC5A-CB1A665CFE1A</gtr:id><gtr:impact>Audioslide presentation of a paper by Claudia Manzoni showing how fibroblast cells from people with Parkinson's disease caused by mutations in LRRK2 react to starvation.</gtr:impact><gtr:outcomeId>56e1590f163169.46800925</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/ukpdc/news-publications/pd-lrrk2-mutations-alter-autophagic-starvation-response</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parkinson's UK Gretschen Amphlet memorial lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B76D7167-08A3-45A0-92A8-6CA8689A33CA</gtr:id><gtr:impact>The lecture was given by Dr Patrick Lewis from UCL (who is a member of the Wellcome/MRC neurodegeneration consortium) and Dr Flaviano Giorgini from the University of Leicester. The subject of the lecture was Parkinson's and the genetic revolution: from genes to treatments , and the entire lecture can be viewed on Youtube on the link below.

Increased exposure.</gtr:impact><gtr:outcomeId>YRbDemZZTXa</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/ukpdc/news-publications/video-parkinsons-genes-treatments-gretschen-amphlet-memorial-lecture-2013</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at Takeda</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8A7BFB93-A575-45C8-A00A-6C5CB07FFB04</gtr:id><gtr:impact>Prof John Hardy presented on the genetic analysis of neurodegenerative disease to staff at phramaceutical company Takeda in Cambridge, UK.</gtr:impact><gtr:outcomeId>56e157e12d4d85.70317174</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PUK site visit - 2012</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>55C6EEBA-FF6A-4052-A568-91D92F7971D3</gtr:id><gtr:impact>Site visits from the public and special interest groups to provide insight into how research is being done on Parkinson's disease.

Hosted by Marta Delgado.

--</gtr:impact><gtr:outcomeId>H1foVaxgdQZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>XX World Congress on Parkinson's Disease and Related Disorders</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C499F326-4CC6-43EE-9FFD-30795FFC02B8</gtr:id><gtr:impact>John Hardy was invited to give a presentation on Synuclein and Synucleinopathies. This reached an audience of researchers from across the globe. This took place in Geneva, Switzerland in December 2013.</gtr:impact><gtr:outcomeId>56e14e888d5403.37031326</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PUK site visit - 2011</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CEC8BC50-A149-41E7-BC6F-1547A9697AAE</gtr:id><gtr:impact>Site visit from Parkinson's UK members, to provide insight into how research is being done on Parkinson's disease.

http://www.ucl.ac.uk/ukpdc/news-publications/video-lrrk2-patrick-lewis-parkinsons-uk-site-visit

Video of visit available to public.</gtr:impact><gtr:outcomeId>VPasgJ17jSm</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New York Times article</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ADF9704A-68AD-4B0C-8194-A3EC59669314</gtr:id><gtr:impact>Press release about the discovery of the new Alzheimer's disease gene (TREM2).</gtr:impact><gtr:outcomeId>56e15672ce4ea3.15543999</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.nytimes.com/2012/11/15/health/gene-mutation-that-hobbles-immune-response-is-linked-to-alzheimers.html</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>XXIst World Congress of Neurology</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>78335ED6-F3D3-47FB-A069-FB0360D637D1</gtr:id><gtr:impact>Plenary Talk given by John Hardy - &amp;quot;Impact of genetics on the field of neurology&amp;quot;. Took place in Vienna in September 2013.</gtr:impact><gtr:outcomeId>56e14ebf1ad491.87891390</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neurodegenerative Diseases Initiative cross-consortium video</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CBA3A63D-A391-4ABC-BC4E-4923126F933C</gtr:id><gtr:impact>Granny Marsh is 90 years old and living a wonderful life, but many her age suffer from degenerative brain diseases.

Whilst the EU spends approximately &amp;pound;108 billion a year supporting those with dementias, currently less than one hundredth of that is spent on research. As yet there are no cures.

That's why the Wellcome Trust and MRC are funding an international team of scientists to investigate Alzheimer's, Parkinson's and Motor Neuron Disease.



Awareness, very positive feedback.</gtr:impact><gtr:outcomeId>rtDkGnthusL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://youtu.be/VcIiHmkbDts</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Congress of Brain, Behavior and Emotions</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C1E5E543-78D5-4084-8798-6AD3C30673E0</gtr:id><gtr:impact>Interactive Keynote Lecture entitled &amp;quot;The puzzling genetics of neurologic and psychiatric disorders: Where are we now?&amp;quot;. This lecture was given to an international group of scientists and the audience consisted of a few hundred people. It was held at the Palais de Congr&amp;egrave;s in Montreal in April 2014.</gtr:impact><gtr:outcomeId>56e155df9784f3.02055447</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Degenerating Brains public symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7964637F-2EE6-4CC3-BE13-C3ED8B7B4021</gtr:id><gtr:impact>The &amp;quot;Degenerating Brains&amp;quot; public symposium was held on the 13th March 2013, as part of Brain Awareness Week. Around 250 people showed up to hear Professors John Hardy (UCL), Chris Shaw (KCL) and David Rubinsztein (Cambridge) discuss new discoveries in neurodegenerative diseases and how they might impact drug treatment.

Very positive feedback, increased exposure.</gtr:impact><gtr:outcomeId>F3wQL7CXnn5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/ukpdc/news-publications/video-public-lecture-degenerating-brains-new-research-ad-pd-mnd</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cosy Science</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E086F335-9E35-41E3-88F9-87E961F4226D</gtr:id><gtr:impact>John Hardy gave a talk on the genetic analysis of neurological disease to a lay audience, without any visual aids, in the function room of a pub. This was organised as part of a series of science caf&amp;eacute;s in London in May 2013.</gtr:impact><gtr:outcomeId>56e156c29a7509.35322900</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL MSc Genetics of Human Disease lectures</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>05828B0F-BD66-40AE-ABD3-66C8C6BD0D76</gtr:id><gtr:impact>Various researchers including John Hardy, Helene Plun-Favreau and Nick Wood lectured to taught postgraduate students on such topics as &amp;quot;Cellular and Molecular Mechanisms of Disease&amp;quot; and &amp;quot;Genetics of Neurological Disease&amp;quot; each year between 2009 and 2015.</gtr:impact><gtr:outcomeId>56e14f90f1f599.91744965</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>40545</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 - BSF - A Role For De Novo Mutations In Parkinson's Disease - jbras</gtr:description><gtr:fundingOrg>Bachmann-Strauss Dystonia &amp; Parkinson Foundation</gtr:fundingOrg><gtr:id>28207E7B-CADC-445A-86AC-C424BC3A2666</gtr:id><gtr:outcomeId>56e0607129b725.11766684</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34957</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2013 - PUK - How is the tau gene involved in Parkinson's? - rdesilva</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>K-1212</gtr:fundingRef><gtr:id>7AA04F8B-3441-4DC2-AF17-7C86FCC66596</gtr:id><gtr:outcomeId>56e133c948ad27.49784323</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>333229</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - PUK - What is the link between Gaucher's disease and Parkinson's? - aschapira</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>G-1104</gtr:fundingRef><gtr:id>282A3136-AF64-4923-B162-61A34195F595</gtr:id><gtr:outcomeId>56e05f908b4201.18578029</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>145600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - PUK - Understanding the role of the Fbxo7 gene in Parkinson's - dalessi</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>H-1101</gtr:fundingRef><gtr:id>CA402DBA-95C6-4512-BF41-1995E6C22BC8</gtr:id><gtr:outcomeId>56e053d6a008c1.86661360</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 - MJFF - Generation of Phospho-Ser65 Parkin and Phospho-Thr257 PINK1 Pre-clinical Monoclonal Antibodies and Characterization of Total PINK1 Pre-clinical Monoclonal Antibodies - mmuqit</gtr:description><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>D731A426-0470-467A-ABB5-19822E1594C2</gtr:id><gtr:outcomeId>56e13a8e397220.57286294</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>129110</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - MRC - Clinical Research Fellowship - amcneill</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7016BA39-0911-4DFA-9572-B94F9C8FF973</gtr:id><gtr:outcomeId>BnzearZyzMH0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - AMS - Starter Grants for Clinical Lecturers - sgandhi</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>E75520F5-7618-454C-BF99-20B6579D0931</gtr:id><gtr:outcomeId>YAJPiiaW8yb0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90580</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - PUK - PhD Studentship</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>H-1006</gtr:fundingRef><gtr:id>2C9680F4-9800-400A-A6AA-A0B0BE6FFD74</gtr:id><gtr:outcomeId>jJac158goNs0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - MJFF - Generation of Monoclonal and Polyclonal Antibodies against LRRK1 - dalessi</gtr:description><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>C51DC6D2-3F09-49E3-B864-EF2E0536920D</gtr:id><gtr:outcomeId>56e13b22d75e23.33112390</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>118380</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 - PUK - A new fruit fly model of Parkinson's - awhitworth</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>G-1201</gtr:fundingRef><gtr:id>D022E846-625E-4019-A744-25E3E88BFE93</gtr:id><gtr:outcomeId>56e051c7d54638.25134601</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2013 - Wolfson - LWENC</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>The Wolfson Foundation</gtr:fundingOrg><gtr:id>4D06DD2D-AC78-4337-9684-2F640A2B995F</gtr:id><gtr:outcomeId>QZM77rwEsmL</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>129112</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - MRC - Clinical Research Training Fellowship - usheerin</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>64DB8049-1671-42BF-A64B-70E4999F58A0</gtr:id><gtr:outcomeId>56e13705dadf40.49822405</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>106835</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - PUK - Can a diabetes drug also help people with Parkinson's? - mduchen</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>G-1101</gtr:fundingRef><gtr:id>F4C2B06F-516A-481E-9AAE-0D137C89223A</gtr:id><gtr:outcomeId>56e053720934b0.17808957</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>339000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - NIHR - Equipment Grant - nwood</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>E70E6247-5C0D-466E-AC02-8E851EB6E651</gtr:id><gtr:outcomeId>CEuqNKYaTvh0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>483730</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2008 - PUK - How does the PINK1 gene cause nerve cell death in Parkinson's? - aabramov</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>F-0806</gtr:fundingRef><gtr:id>425554B3-63F7-438E-9612-AFECD47D574F</gtr:id><gtr:outcomeId>56e1353e192931.01408493</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>319334</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2010 - PUK - How does Parkinson's spread throughout the brain? - trevesz</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>G-1004</gtr:fundingRef><gtr:id>2239F0AD-74C4-4560-9168-038F308D4511</gtr:id><gtr:outcomeId>56e1348097f997.81005352</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180526</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2014 - JPND - PERADES: Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease using multiple powerful cohorts, focussed epigenetics and Stem cell metabolomics - jwilliams</gtr:description><gtr:fundingOrg>JPND Research</gtr:fundingOrg><gtr:id>754DCDFE-9309-432D-A9AB-B36EA8E7B94B</gtr:id><gtr:outcomeId>56e050c270b227.65072827</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2008 - NIHR - Senior Investigator - nwood</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>718EA58D-71E5-48B5-B1C3-059C02B87DB0</gtr:id><gtr:outcomeId>r4iGivPYaQC0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2010 - MJFF - Development of Selective LRRK2 Inhibitors - dalessi</gtr:description><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>4338AA55-3343-4700-9F00-227AE55B3CFC</gtr:id><gtr:outcomeId>56e139efcbf320.05041832</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1268396</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 - ERC - ERC Starting Grant - awhitworth</gtr:description><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>4C26C585-CC98-40A8-B97B-DBC7996B33A1</gtr:id><gtr:outcomeId>56e0522cd3e0e7.79521497</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>349994</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2014 - AS - Postdoctoral Research Fellowship - jbras</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Alzheimer?s Society</gtr:fundingOrg><gtr:id>A0222F33-4BE2-4F31-9897-8B190571A909</gtr:id><gtr:outcomeId>56e0503d7cf842.16081559</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>315000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - PUK - Filling the genetic gaps in Parkinson's - nwood</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>G-1107</gtr:fundingRef><gtr:id>A86BE547-114F-44CC-B2AF-8837C26E43DC</gtr:id><gtr:outcomeId>VHz1yYNkbMo0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 - MJFF - Characterizing Region Specific Splice Isoforms of LRRK2 - jhardy</gtr:description><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>3F152392-1230-4FC7-A956-2F11585FADE1</gtr:id><gtr:outcomeId>56e139ab1c32e5.91790132</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 - MJFF - Development of an HTS Assay to Break the Alpha-Synuclein-Glucocerebrosidase Feedback Loop - aschapira</gtr:description><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>EB42657D-66DF-42AA-92E8-864379329E3C</gtr:id><gtr:outcomeId>56e1395e95e975.64919845</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>661636</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - WT - Equipment Grant - nwood</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>F544AACA-884D-472A-B4C1-EBB00E821EA9</gtr:id><gtr:outcomeId>FK2fDHSwTsk0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75281</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2010 - BBSRC - BBSRC Industrial CASE Partnership Grant - dalessi</gtr:description><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>83B7A005-7C2D-47CD-99DD-FD05609A799E</gtr:id><gtr:outcomeId>56e13893bd0739.29008259</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - MJFF - Analysis of LRRK2 Antibodies - dalessi</gtr:description><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>732FCD58-924A-44CC-8DB3-96A1FEC20E32</gtr:id><gtr:outcomeId>56e13adcb7b350.09933127</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 - PUK - Looking for genes linked with dementia with Lewy bodies - jbras</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>K-1204</gtr:fundingRef><gtr:id>4F515365-EC69-48E0-88EB-C58C9E2D5D3B</gtr:id><gtr:outcomeId>56e136443323f3.23978228</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2013 - NIHR - BRC for NIHR Rare Diseases Translational Research Collaboration: Autosomal Dominant Parkinson's disease - nwood</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>9A44CFC6-11B4-41A8-ADA9-BE5C147ED9FD</gtr:id><gtr:outcomeId>Way4wKSBhCg</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2010 - MJFF - Exploiting Ser910/935 Phosphorylation and 14-3-3 Binding to Develop Biomarkers for LRRK2 Activity - dalessi</gtr:description><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>DE813274-CC07-41C1-B57A-56E2CA5F8D2E</gtr:id><gtr:outcomeId>56e13a355b5fa2.92216097</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>292590</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2009 - PUK - Project Grant - nwood</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:id>E320641A-6D6E-4CB1-B234-A545058F625E</gtr:id><gtr:outcomeId>rujBsRiGXvB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>466500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>2009 - NIHR - UCL/UCLH Comprehensive Biomedical Centre Capital Project - nwood</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>6D5572FA-365E-447E-8630-298E5B2A574A</gtr:id><gtr:outcomeId>rs6c2mdgLgN0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2013 - MRC - Centenary Award - usheerin</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7DAE4891-5FB7-403A-AC0B-34BE1318381F</gtr:id><gtr:outcomeId>AevxMRLK2nr</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2010 - PUK - Career development award - plewis</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>F-1002</gtr:fundingRef><gtr:id>7AEAD3F0-864B-408A-A45B-DB092FC595D3</gtr:id><gtr:outcomeId>56e05321e8ecc0.08420114</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>714181</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2013 - JPND - Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease - nwood</gtr:description><gtr:fundingOrg>JPND Research</gtr:fundingOrg><gtr:fundingRef>MR/L501554/1</gtr:fundingRef><gtr:id>8CAC1FA4-DF0F-4CFD-B4F2-76724886B5ED</gtr:id><gtr:outcomeId>sKWjZPPS54t</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>84945</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2009 - PUK - What does the PINK1 gene do in nerve cells? - dalessi</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>H-0901</gtr:fundingRef><gtr:id>3F6D947A-16BF-4BF1-909D-80EED3515FD9</gtr:id><gtr:outcomeId>56e0542fe25534.53630096</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - MJFF - Investigating Signaling Pathway Dysfunction Linked to LRRK2 - plewis</gtr:description><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>18096BF1-2393-4045-9209-A90D6BA311D6</gtr:id><gtr:outcomeId>56e13907edcf19.01460978</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>208751</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2010 - PUK - Are Lewy bodies behind dopamine nerve cell death? - mcooper</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>G-0910</gtr:fundingRef><gtr:id>96D90B33-64FE-42EB-8999-1677FF653112</gtr:id><gtr:outcomeId>56e134e2905155.97923161</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>37000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 - MJFF - Combining Mass Spectrometry with Genetic and Pharmacological Approaches to Discover and Validate LRRK2 Substrates - nwood</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>90544707-8B7F-4142-B0B9-3127060B4C34</gtr:id><gtr:outcomeId>56e04fa54fb6e6.07345331</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 - PUK - Fat: a new source of stem cells for Parkinson's? - jtaanman</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>K-1201</gtr:fundingRef><gtr:id>FF199F38-C3CB-4F41-B4FB-CB95626EC15C</gtr:id><gtr:outcomeId>56e0549d9c94b3.60381255</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>248629</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - PUK - Career development award - lalvarez</gtr:description><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>F-1101</gtr:fundingRef><gtr:id>226FF4C1-6FF2-4D9F-84D4-62A3C1A991FF</gtr:id><gtr:outcomeId>56e0529d7f58c3.12115568</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34904</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 - PUK - How does alpha-synuclein move from cell to cell? - mcooper</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>K-1202</gtr:fundingRef><gtr:id>03A23127-EE20-44A8-85F4-355A565F594A</gtr:id><gtr:outcomeId>56e134188f24d9.13322782</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>109794</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2011 - PUK - Should we treat Parkinson's earlier? - kbhatia</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>G-1009</gtr:fundingRef><gtr:id>CB363E96-37F2-4316-8F76-DE65DAB1A713</gtr:id><gtr:outcomeId>56e136a3636217.61411537</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>357022</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2010 - MJFF - Investigating Signaling Pathway Dysfunction Linked to LRRK2 - plewis</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>CA721C63-6345-4040-B4E4-7F6624707756</gtr:id><gtr:outcomeId>HDykQMSXx8Z0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>576979</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2014 - JPND - Risk and Modifying factors in Fronto-Temporal Dementia - jhardy</gtr:description><gtr:fundingOrg>JPND Research</gtr:fundingOrg><gtr:fundingRef>MR/L501542/1</gtr:fundingRef><gtr:id>B3F870D6-6D30-41B7-B638-0061FBD51D33</gtr:id><gtr:outcomeId>56e0515b2e7329.53368844</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Database of genetic variants.</gtr:description><gtr:id>A29DBEBB-9069-4683-96C8-08AD2A7E3238</gtr:id><gtr:impact>Lookup and validation of genetic variants across cases and research groups.</gtr:impact><gtr:outcomeId>56e13e3a0d1126.38279823</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Variant database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Database for tracking the storage and processing of research samples.</gtr:description><gtr:id>FEDCCF7A-D6A2-4E7F-B970-8B34D7458885</gtr:id><gtr:impact>Improved sample management, tracking, conservation, and control.</gtr:impact><gtr:outcomeId>56e13f4c5355d8.92793008</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Sample management database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Database framework for recruitment and for entering study data via electronic forms, including directly from participants,</gtr:description><gtr:id>78EB94D0-24C2-4D80-8364-475B7126B224</gtr:id><gtr:impact>Consolidation of research studies, common data model deployed across internal and external groups, improved data capture and study management, use UCLH hospital setting.</gtr:impact><gtr:outcomeId>56e13f03445c37.77183082</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Research data capture</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Database for managing clinical and research datasets linked to samples.</gtr:description><gtr:id>5F64C672-4942-4AA7-891E-65FD535F031D</gtr:id><gtr:impact>Improved selection and linking, better characterised cohorts, sample conservation, less overlap and more sharing and reuse of data.</gtr:impact><gtr:outcomeId>56e13de42888d9.93642487</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Research database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Alex Whitworth. New transgenic lines to model recently described PD genes, including; GBA (WT, N370S, L444P) and Vps35 (WT, R524W, D620N, L774M).</gtr:description><gtr:id>DD8F5A4A-231C-42A8-B4BB-159A2C29BC1C</gtr:id><gtr:impact>Alex Whitworth. New transgenic lines to model recently described PD genes, including; GBA (WT, N370S, L444P) and Vps35 (WT, R524W, D620N, L774M).</gtr:impact><gtr:outcomeId>56e14460045041.10605436</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Transgenic lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Database of benign genetic variability, used for filtering in exome sequencing experiments.</gtr:description><gtr:id>2861213A-9A2A-4294-AFB9-EC4FCE88D7FD</gtr:id><gtr:impact>Application in research.</gtr:impact><gtr:outcomeId>PtWzQcyoXY1</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Healthy exomes database</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Dario Alessi. In collaboration developed improved highly selective LRRK2 inhibitors.
 Elaboration of the first brain penetrable inhibitor (HG-10-102-01) that can be administered to mice by IP injection or oral gavage that effectively suppress LRRK2 in brain (Choi et al. 2012). 
 Helped in the characterisation of by far the most selective LRRK2 inhibitor described to date (GSK2578215A) that only targets LRRK2 out of ~400 other protein kinases evaluated (Reith et al. 2012).</gtr:description><gtr:id>E7DA85FA-1E31-47E3-8B67-13EFAF9B7F0B</gtr:id><gtr:impact>For each of these inhibitors we have generated large supplies and have distributed these freely to the scientific community with no strings attached.</gtr:impact><gtr:outcomeId>56e144c218cbb9.48304120</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>LRRK2 inhibitors</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Database of patients with copy number variation</gtr:description><gtr:id>D522E53E-8CAA-45E1-864E-75C3ED6BDE80</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:outcomeId>inVpW2fMN9t</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Copy number variation database</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BA8D107A-5B83-4932-9A1D-A8153C3254E2</gtr:id><gtr:title>The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f54cad0ab0877e543fc660186cd44ff0"><gtr:id>f54cad0ab0877e543fc660186cd44ff0</gtr:id><gtr:otherNames>Guerreiro RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_20594621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A27C84D7-6C43-4604-8C64-551BEF2402EC</gtr:id><gtr:title>GTP binding and intramolecular regulation by the ROC domain of Death Associated Protein Kinase 1.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac4edfbae5d50e10d7cbcc2a540efcf0"><gtr:id>ac4edfbae5d50e10d7cbcc2a540efcf0</gtr:id><gtr:otherNames>Jebelli JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>pm_16517_27_23019516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0882894C-3E63-4298-9821-3E02DC1CB7FE</gtr:id><gtr:title>A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9daf1044ffaa78c220fa83b15b9c753"><gtr:id>b9daf1044ffaa78c220fa83b15b9c753</gtr:id><gtr:otherNames>Ferrari R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56e032e754aa02.88783609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08F9680B-1837-4478-B9BF-FE681EDFCEA7</gtr:id><gtr:title>Alzheimer's disease genetics: lessons to improve disease modelling.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f54cad0ab0877e543fc660186cd44ff0"><gtr:id>f54cad0ab0877e543fc660186cd44ff0</gtr:id><gtr:otherNames>Guerreiro RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_16517_27_21787322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D2FF20D-8C1C-4580-B5BB-C29AF7EA788D</gtr:id><gtr:title>Mutations in PNKP cause recessive ataxia with oculomotor apraxia type 4.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/609865d4dd5b805590a0ed599a30249b"><gtr:id>609865d4dd5b805590a0ed599a30249b</gtr:id><gtr:otherNames>Bras J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>56e032397288a9.72818761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC80E963-856B-4924-8489-BB1192C18B69</gtr:id><gtr:title>TREM2 variants in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d14505f1916bc463c5643c1c28d8"><gtr:id>56b2d14505f1916bc463c5643c1c28d8</gtr:id><gtr:otherNames>Guerreiro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_16517_27_23150934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59D0989D-722A-4723-AA5D-4A04A50D08F3</gtr:id><gtr:title>Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80bdbfdd0b1d93ff7f53295d25d425e7"><gtr:id>80bdbfdd0b1d93ff7f53295d25d425e7</gtr:id><gtr:otherNames>Charlesworth G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_16517_27_23200863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>713E0A4B-FBB1-4A5A-A3B2-402422A6FFBA</gtr:id><gtr:title>Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de13990c2de0c88ddd31ad41567d0a50"><gtr:id>de13990c2de0c88ddd31ad41567d0a50</gtr:id><gtr:otherNames>Berg D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>54b7eff4466e94.40567396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E9287FA-752E-443C-A695-88ABB005B575</gtr:id><gtr:title>Etiology and pathogenesis of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_21626550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62085F4B-44A1-4419-9D45-5863F094D172</gtr:id><gtr:title>Brain Penetrant LRRK2 Inhibitor.</gtr:title><gtr:parentPublicationTitle>ACS medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be2e4fa6e78174440beaaa54b66007c"><gtr:id>3be2e4fa6e78174440beaaa54b66007c</gtr:id><gtr:otherNames>Choi HG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1948-5875</gtr:issn><gtr:outcomeId>pm_16517_27_23066449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC4F9A13-C0E4-40E3-9A48-A1F7F58609F4</gtr:id><gtr:title>Computational analysis of the LRRK2 interactome.</gtr:title><gtr:parentPublicationTitle>PeerJ</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56e032395096e1.49763400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93E47CBC-AD27-4D87-8C9E-78C7646542CD</gtr:id><gtr:title>Homozygous TREM2 mutation in a family with atypical frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e296dd12dae090cc5d3853b122648d61"><gtr:id>e296dd12dae090cc5d3853b122648d61</gtr:id><gtr:otherNames>Le Ber I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56e032339fe5d4.40218095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEBB07D2-0A0E-4858-9ED5-5D912B8512DC</gtr:id><gtr:title>Ca2+ is a key factor in a-synuclein-induced neurotoxicity.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8fbb8ccee913c0ad555ab7ec713c5fdd"><gtr:id>8fbb8ccee913c0ad555ab7ec713c5fdd</gtr:id><gtr:otherNames>Angelova PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>5889db2eb17bf9.33586372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56FED443-12A8-4A09-A782-5AD47D041B79</gtr:id><gtr:title>Mitochondria, calcium-dependent neuronal death and neurodegenerative disease.</gtr:title><gtr:parentPublicationTitle>Pflugers Archiv : European journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df3b4dffb07770cf05bb699acad8cfc4"><gtr:id>df3b4dffb07770cf05bb699acad8cfc4</gtr:id><gtr:otherNames>Duchen MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-6768</gtr:issn><gtr:outcomeId>pm_16517_27_22615071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8EE1581-D838-4FC3-81BF-15FEFB6F4979</gtr:id><gtr:title>The non-motor syndrome of primary dystonia: clinical and pathophysiological implications.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_16517_27_21933808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07DF34B9-28C5-4387-909A-0FCFF2BA0835</gtr:id><gtr:title>Cancer and neurodegeneration: between the devil and the deep blue sea.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1a768ac0348b89871dc88cb7217499f"><gtr:id>d1a768ac0348b89871dc88cb7217499f</gtr:id><gtr:otherNames>Plun-Favreau H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>pm_16517_27_21203498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8916E2F8-B5AD-49D3-8357-A812BD1C1084</gtr:id><gtr:title>Genetic analysis of inherited leukodystrophies: genotype-phenotype correlations in the CSF1R gene.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d14505f1916bc463c5643c1c28d8"><gtr:id>56b2d14505f1916bc463c5643c1c28d8</gtr:id><gtr:otherNames>Guerreiro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>pm_16517_27_23649896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C857803-83BA-4ACD-94EA-2922EFA584A5</gtr:id><gtr:title>Priorities in Parkinson's disease research.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0caec30ade954577984e5c21e493cafb"><gtr:id>0caec30ade954577984e5c21e493cafb</gtr:id><gtr:otherNames>Meissner WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>pm_16517_27_21532567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4B963E4-EDAF-42B1-B8D1-9C06FCCE87BF</gtr:id><gtr:title>Moving toward &amp;quot;laboratory-supported&amp;quot; criteria for psychogenic tremor.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/933c853b6f0a20d8ccf3cf131cf4bc87"><gtr:id>933c853b6f0a20d8ccf3cf131cf4bc87</gtr:id><gtr:otherNames>Schwingenschuh P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_21956485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B561C70-17B2-4724-9F85-D3BE195A3623</gtr:id><gtr:title>Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2596d3af9c0ecb02e3af1d191bf271ea"><gtr:id>2596d3af9c0ecb02e3af1d191bf271ea</gtr:id><gtr:otherNames>Gegg ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16517_27_20871098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C285A5A-5E99-42CF-A6CF-B07B0F8765A7</gtr:id><gtr:title>The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5a2b37a3a8be9f6ddf0f9df6e924057"><gtr:id>a5a2b37a3a8be9f6ddf0f9df6e924057</gtr:id><gtr:otherNames>Palmer CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>pm_16517_27_21683788</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D71FD96E-200D-49F4-AB72-6C7CEC2F953F</gtr:id><gtr:title>Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1: analysis of substrate specificity and impact of mutations.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89595fe987700a3e8abaf6a651a6ebad"><gtr:id>89595fe987700a3e8abaf6a651a6ebad</gtr:id><gtr:otherNames>Woodroof HI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>pm_16517_27_22645651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04CE3AB3-5F9D-4EAA-A1C1-82D206EA40B0</gtr:id><gtr:title>Dystonic opisthotonus: a &amp;quot;red flag&amp;quot; for neurodegeneration with brain iron accumulation syndromes?</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_23736975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66B931C5-FA8E-4244-99C9-2C3C4AB3327A</gtr:id><gtr:title>Chaperone-mediated autophagy markers in Parkinson disease brains.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7322e4d45d8d897e3ce8b1d90bde79b"><gtr:id>f7322e4d45d8d897e3ce8b1d90bde79b</gtr:id><gtr:otherNames>Alvarez-Erviti L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>pm_16517_27_20697033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16AE46C8-27E5-476F-9884-4EE037A37836</gtr:id><gtr:title>Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fedc4404d626048147a389c1d14ecc32"><gtr:id>fedc4404d626048147a389c1d14ecc32</gtr:id><gtr:otherNames>Bartolome F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_16517_27_23498975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FD3120E-664C-49D8-809A-2AB9BF62996D</gtr:id><gtr:title>A paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of ?-amyloid production.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d29e073a5779c541d6e74e3267c893e0"><gtr:id>d29e073a5779c541d6e74e3267c893e0</gtr:id><gtr:otherNames>Udayar V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54b7eff2006474.05115237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>112B67A9-C14E-44B6-A867-1C88981525A4</gtr:id><gtr:title>Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79c943d719ca6749410f754081f54667"><gtr:id>79c943d719ca6749410f754081f54667</gtr:id><gtr:otherNames>Ling H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>54b7eff272ea39.93993850</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDE53CA9-6FC1-4402-BC84-5211902C8762</gtr:id><gtr:title>Kinase drug discovery--what's next in the field?</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9144749a896da3325ac3684938ae4935"><gtr:id>9144749a896da3325ac3684938ae4935</gtr:id><gtr:otherNames>Cohen P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>pm_16517_27_23276252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC9EFCE8-A700-49B2-8739-DFCAE9148DD9</gtr:id><gtr:title>Divergent a-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bc79c6d1bd646b80a6e83cb1ed16ead"><gtr:id>8bc79c6d1bd646b80a6e83cb1ed16ead</gtr:id><gtr:otherNames>Mamais A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>pm_16517_27_23747310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5FCA9C5-FD13-4C0B-A78C-198EA8D5A89D</gtr:id><gtr:title>A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_16517_27_22577228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55AFB2B0-A40B-44AC-AAF9-983B18B5ABE7</gtr:id><gtr:title>Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fd07a9b4cf0377237a98ea0d1dcf8d9"><gtr:id>1fd07a9b4cf0377237a98ea0d1dcf8d9</gtr:id><gtr:otherNames>Kefalopoulou Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>56e03232ad8b34.63162270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C446FC91-FAEA-421B-9B92-CAB1D4F9BF77</gtr:id><gtr:title>Age-associated changes in gene expression in human brain and isolated neurons.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a93647d799d53d5111001b3b241fdab"><gtr:id>1a93647d799d53d5111001b3b241fdab</gtr:id><gtr:otherNames>Kumar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>54b7eff35d51a0.67763906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67D120F8-E032-480B-8CB4-B0ED5D7C9CD7</gtr:id><gtr:title>Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf8b293c57e2abbe75629b0924e21ef0"><gtr:id>cf8b293c57e2abbe75629b0924e21ef0</gtr:id><gtr:otherNames>Nalls MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5464b8c62e6471.73557790</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51BB42A7-0643-4ADF-9E66-F1F11D7FE6EA</gtr:id><gtr:title>Psychogenic facial movement disorders: clinical features and associated conditions.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e64c19144d070bb30e6ebc251ede68"><gtr:id>54e64c19144d070bb30e6ebc251ede68</gtr:id><gtr:otherNames>Fasano A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_23033125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58CC5C4D-3E70-4542-87C3-8895F653B38C</gtr:id><gtr:title>Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a95b8ae7d8e0ad11a24b2c45b8093ff5"><gtr:id>a95b8ae7d8e0ad11a24b2c45b8093ff5</gtr:id><gtr:otherNames>Stockner H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22744819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42C75689-FA70-41AA-8E05-1951A77E7CDA</gtr:id><gtr:title>Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5fd8a036b6ccf0bb9a8fec23f69321d"><gtr:id>f5fd8a036b6ccf0bb9a8fec23f69321d</gtr:id><gtr:otherNames>Cruchaga C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>54b7eff172e4f8.13825956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5F3606D-DC69-4763-9485-F91EA31C5F72</gtr:id><gtr:title>The genetics of dystonia: new twists in an old tale.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80bdbfdd0b1d93ff7f53295d25d425e7"><gtr:id>80bdbfdd0b1d93ff7f53295d25d425e7</gtr:id><gtr:otherNames>Charlesworth G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_16517_27_23775978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>977C674E-7803-4572-9FD7-7547701F03C7</gtr:id><gtr:title>Young-onset parkinsonism due to homozygous duplication of a-synuclein in a consanguineous family.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a710ca1824f44073ef7bb8d23ab87321"><gtr:id>a710ca1824f44073ef7bb8d23ab87321</gtr:id><gtr:otherNames>Kojovic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_23283657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9CB9D88-7C8B-459B-94F0-5CAAD4B11006</gtr:id><gtr:title>Mitophagy and Parkinson's disease: the PINK1-parkin link.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>pm_16517_27_20736035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0237A81-68E2-4728-956B-F2D5B89908A8</gtr:id><gtr:title>Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b62a53649f238c8ef4ad4969252d6c4b"><gtr:id>b62a53649f238c8ef4ad4969252d6c4b</gtr:id><gtr:otherNames>Cooper JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>56e03233c4c2c2.06688466</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF4541CA-4F65-424D-A638-EDBEE1027187</gtr:id><gtr:title>Interplay between Polo kinase, LKB1-activated NUAK1 kinase, PP1?MYPT1 phosphatase complex and the SCF?TrCP E3 ubiquitin ligase.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/027db9c3b84b87202a8838ca43705bf5"><gtr:id>027db9c3b84b87202a8838ca43705bf5</gtr:id><gtr:otherNames>Banerjee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56e03237785a10.84472381</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>561BFDB0-D4F7-4527-AFF7-84DCA82BFFE8</gtr:id><gtr:title>The pallidopyramidal syndromes: nosology, aetiology and pathogenesis.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/697536feebefd233256c0907479ff552"><gtr:id>697536feebefd233256c0907479ff552</gtr:id><gtr:otherNames>Kara E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>pm_16517_27_23817214</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB0D9786-42EA-4FE8-A6BE-C33DC98906F7</gtr:id><gtr:title>Tau acts as an independent genetic risk factor in pathologically proven PD.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80bdbfdd0b1d93ff7f53295d25d425e7"><gtr:id>80bdbfdd0b1d93ff7f53295d25d425e7</gtr:id><gtr:otherNames>Charlesworth G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_22221882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB8673D1-FA16-4686-8B16-9FD9A092811C</gtr:id><gtr:title>THAP1 mutations and dystonia phenotypes: genotype phenotype correlations.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7683c72a503be0311ba813667c505f75"><gtr:id>7683c72a503be0311ba813667c505f75</gtr:id><gtr:otherNames>Xiromerisiou G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22903657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A33D2BFE-70CA-4FF9-8387-327F7C825EF6</gtr:id><gtr:title>Acetylcholine and antibodies against the acetylcholine receptor protect neurons and astrocytes against beta-amyloid toxicity.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17cc624b62cdd63a7a3a048af712b027"><gtr:id>17cc624b62cdd63a7a3a048af712b027</gtr:id><gtr:otherNames>Kamynina AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn><gtr:outcomeId>pm_16517_27_23353645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92C21A03-9E3E-4114-AA7C-6CAAC3693166</gtr:id><gtr:title>Investigating the utility of human embryonic stem cell-derived neurons to model ageing and neurodegenerative disease using whole-genome gene expression and splicing analysis.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bf41e3616627e43c288596e8b1c932e"><gtr:id>7bf41e3616627e43c288596e8b1c932e</gtr:id><gtr:otherNames>Patani R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>pm_16517_27_22681703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16FF2918-EAB7-4E37-BD06-500A0BFCCF12</gtr:id><gtr:title>A systematic screening to identify de novo mutations causing sporadic early-onset Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46e73b422d17d863d689d21fb0a952eb"><gtr:id>46e73b422d17d863d689d21fb0a952eb</gtr:id><gtr:otherNames>Kun-Rodrigues C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56e0323b4374b4.07345543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>977B0736-573A-4307-B136-0E37F7BE5B03</gtr:id><gtr:title>Genetic comorbidities in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf8b293c57e2abbe75629b0924e21ef0"><gtr:id>cf8b293c57e2abbe75629b0924e21ef0</gtr:id><gtr:otherNames>Nalls MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16517_27_24057672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC141D0E-4716-4762-BF08-D52111B088FD</gtr:id><gtr:title>Study of the genetic variability in a Parkinson's Disease gene: EIF4G1.</gtr:title><gtr:parentPublicationTitle>Neuroscience letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e8088f2d6e90105cd78b127c6516c9f"><gtr:id>2e8088f2d6e90105cd78b127c6516c9f</gtr:id><gtr:otherNames>Tucci A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0304-3940</gtr:issn><gtr:outcomeId>pm_16517_27_22561553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8F4339A-A4F5-4718-8281-750B68019632</gtr:id><gtr:title>Mitochondrial dysfunction in glaucoma: understanding genetic influences.</gtr:title><gtr:parentPublicationTitle>Mitochondrion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebf70e1f91c833199ee8b29def2e9538"><gtr:id>ebf70e1f91c833199ee8b29def2e9538</gtr:id><gtr:otherNames>Lascaratos G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1567-7249</gtr:issn><gtr:outcomeId>pm_16517_27_22138560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE6065D9-B9B5-43FA-9AFF-66020C59EB93</gtr:id><gtr:title>NOTCH3 variants and risk of ischemic stroke.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a23c8e8d4548370868b84918636bcb45"><gtr:id>a23c8e8d4548370868b84918636bcb45</gtr:id><gtr:otherNames>Ross OA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54b7eff22a80b2.86940651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB68A432-7B67-48A5-AC4C-48475E542A20</gtr:id><gtr:title>Polygenic risk of Parkinson disease is correlated with disease age at onset.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfb50ad82a115894d592e09569cffa3f"><gtr:id>dfb50ad82a115894d592e09569cffa3f</gtr:id><gtr:otherNames>Escott-Price V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>5697b16b9e4025.22422479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D5F817C-578F-4A03-A58B-9FB5D7622A9E</gtr:id><gtr:title>The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/503273474c456315c93d79baa7a3978b"><gtr:id>503273474c456315c93d79baa7a3978b</gtr:id><gtr:otherNames>Dzamko N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16517_27_22723946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB365317-55F3-4D1E-9376-BC23D7689FDF</gtr:id><gtr:title>Rare variants in LRRK1 and Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c29f4932a9c0faa81ab4ed1cecedefd0"><gtr:id>c29f4932a9c0faa81ab4ed1cecedefd0</gtr:id><gtr:otherNames>Schulte EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1364-6745</gtr:issn><gtr:outcomeId>pm_16517_27_24241507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93E61CCA-FE7E-4A8A-BC56-64ECCB5A726A</gtr:id><gtr:title>Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22550031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>758629C8-63F2-40B8-A20E-5780B8CBA29C</gtr:id><gtr:title>Characterisation and validation of insertions and deletions in 173 patient exomes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e624c5192e4cb8e4e04042cdb89976af"><gtr:id>e624c5192e4cb8e4e04042cdb89976af</gtr:id><gtr:otherNames>Lescai F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16517_27_23251486</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D88054D5-5B9F-4159-9F2F-C4DEDA7652FB</gtr:id><gtr:title>Genetic, structural, and molecular insights into the function of ras of complex proteins domains.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/865abf3616d9e50b08ef99c603e1db55"><gtr:id>865abf3616d9e50b08ef99c603e1db55</gtr:id><gtr:otherNames>Civiero L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>56e03232eaeaa3.74742715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C413C2E4-0557-416B-9F89-B6972CD82781</gtr:id><gtr:title>The significance of a-synuclein, amyloid-? and tau pathologies in Parkinson's disease progression and related dementia.</gtr:title><gtr:parentPublicationTitle>Neuro-degenerative diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a124d1eb2194aabd08d9c85e61a281e8"><gtr:id>a124d1eb2194aabd08d9c85e61a281e8</gtr:id><gtr:otherNames>Compta Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1660-2854</gtr:issn><gtr:outcomeId>54b7eff2c17db8.93212094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA32502C-A168-4680-B367-2879998AAFC9</gtr:id><gtr:title>The complex I subunit NDUFA10 selectively rescues Drosophila pink1 mutants through a mechanism independent of mitophagy.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d5406f6337b9d82fdb4aa125ace837"><gtr:id>a5d5406f6337b9d82fdb4aa125ace837</gtr:id><gtr:otherNames>Pogson JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>56e032386c2a34.74673207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F4E7923-6A34-45AB-B8E3-B07887E27CDA</gtr:id><gtr:title>Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/475d877ceec760cc4db02f32a29b38b3"><gtr:id>475d877ceec760cc4db02f32a29b38b3</gtr:id><gtr:otherNames>Osellame LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>pm_16517_27_23707074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEA56032-6C2C-49E1-9C0D-D397EF9AA97C</gtr:id><gtr:title>Mutations in the autoregulatory domain of ?-tubulin 4a cause hereditary dystonia.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a59fbd288093fca2ace1bf37b42241"><gtr:id>13a59fbd288093fca2ace1bf37b42241</gtr:id><gtr:otherNames>Hersheson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>pm_16517_27_23424103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98184E41-83A0-4933-B9C1-4DC35B8D0594</gtr:id><gtr:title>Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65eb931f142b9d0a96c1e2e4b5b1f6a7"><gtr:id>65eb931f142b9d0a96c1e2e4b5b1f6a7</gtr:id><gtr:otherNames>Hudson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16517_27_23645593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC5D2983-E190-4BB6-82A8-CC2403044B89</gtr:id><gtr:title>Discovery of potent and selective covalent inhibitors of JNK.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2a42f54432a63b7a88ae42e6aa48538"><gtr:id>b2a42f54432a63b7a88ae42e6aa48538</gtr:id><gtr:otherNames>Zhang T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>pm_16517_27_22284361</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4A36D58-CD16-4281-91F7-042FC2725941</gtr:id><gtr:title>Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b3378769e4c0c07ac78280d4ccf7e51"><gtr:id>6b3378769e4c0c07ac78280d4ccf7e51</gtr:id><gtr:otherNames>Deng X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn><gtr:outcomeId>pm_16517_27_24239623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBE47682-2195-4301-9C4D-BF974A654298</gtr:id><gtr:title>Genome-wide association studies: the key to unlocking neurodegeneration?</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe26393ce1a826c37d2c03b54270978"><gtr:id>7fe26393ce1a826c37d2c03b54270978</gtr:id><gtr:otherNames>Gandhi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>56e0315b838626.13863202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44873AAD-8B4F-48D3-921E-760DF8833CF4</gtr:id><gtr:title>SREBF1 links lipogenesis to mitophagy and sporadic Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/126cf83db76c0cfe067a140df0997fb2"><gtr:id>126cf83db76c0cfe067a140df0997fb2</gtr:id><gtr:otherNames>Ivatt RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>56e03238affad7.51634745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2919625F-9EB2-417E-AAA4-BFB235399A45</gtr:id><gtr:title>Effects of five Ayurvedic herbs on locomotor behaviour in a Drosophila melanogaster Parkinson's disease model.</gtr:title><gtr:parentPublicationTitle>Phytotherapy research : PTR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed0d6006b5bb7be462fb0364020ce187"><gtr:id>ed0d6006b5bb7be462fb0364020ce187</gtr:id><gtr:otherNames>Jansen RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0951-418X</gtr:issn><gtr:outcomeId>56e032384ad737.36834342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0EDED45-8932-4272-BE46-2FDE385FFF86</gtr:id><gtr:title>Glucocerebrosidase and Parkinson disease: Recent advances.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>56e0323a98d7e7.34533792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C4C378B-26A4-4159-AB63-8AA62855672C</gtr:id><gtr:title>Stereotypies: a critical appraisal and suggestion of a clinically useful definition.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3948ace15600c52fdd5dc8b73b1e55c"><gtr:id>f3948ace15600c52fdd5dc8b73b1e55c</gtr:id><gtr:otherNames>Edwards MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22161914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B267E8BF-537C-49DF-B84A-FAE9A54E6633</gtr:id><gtr:title>A tangled web - tau and sporadic Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ca09ebb1473b9780612d7b5d9dafef"><gtr:id>68ca09ebb1473b9780612d7b5d9dafef</gtr:id><gtr:otherNames>Wray S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>pm_16517_27_21423457</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E624BD5-D9A0-4C9E-8F81-219FB0D88378</gtr:id><gtr:title>Exome sequencing identifies 2 novel presenilin 1 mutations (p.L166V and p.S230R) in British early-onset Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc6f5d980b9f26a631bb27b333a684ff"><gtr:id>fc6f5d980b9f26a631bb27b333a684ff</gtr:id><gtr:otherNames>Sassi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>54b7eff48d7e13.61110773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>662A058F-A9F4-4619-9133-4C01EA4B2793</gtr:id><gtr:title>Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fc9b26a4f240104f4f5378597d75aff"><gtr:id>0fc9b26a4f240104f4f5378597d75aff</gtr:id><gtr:otherNames>Trabzuni D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>54b7eff335ca32.08703119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0515A8C-0DAC-4E9A-A3E1-F8C992344AB2</gtr:id><gtr:title>Lysosomal storage disorders and iron.</gtr:title><gtr:parentPublicationTitle>International review of neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/388af7ec97f0f04e969c2b8fd3316906"><gtr:id>388af7ec97f0f04e969c2b8fd3316906</gtr:id><gtr:otherNames>Bras JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0074-7742</gtr:issn><gtr:outcomeId>54b7eff24fa546.35729911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CA6EF60-4522-4677-84B5-A4A6B33F7A74</gtr:id><gtr:title>Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a33f41877539feb314d5f4801ac4aa0b"><gtr:id>a33f41877539feb314d5f4801ac4aa0b</gtr:id><gtr:otherNames>Naj AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_16517_27_21460841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAE83377-9562-49FC-B0B6-A0200D48B1B9</gtr:id><gtr:title>Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1.</gtr:title><gtr:parentPublicationTitle>Experimental cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acbf1c12d3659fe065da359d7fc12a70"><gtr:id>acbf1c12d3659fe065da359d7fc12a70</gtr:id><gtr:otherNames>Kieper N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-4827</gtr:issn><gtr:outcomeId>pm_16517_27_20064504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0816DF4-EE54-41C1-B464-CD4D11BC769C</gtr:id><gtr:title>The role of the mitochondrial NCX in the mechanism of neurodegeneration in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af3137ae30d800bbf896d7631ffa4d13"><gtr:id>af3137ae30d800bbf896d7631ffa4d13</gtr:id><gtr:otherNames>Wood-Kaczmar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>pm_16517_27_23224884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17C18CBE-CFE9-4412-A53D-7C76B1133DA9</gtr:id><gtr:title>Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56e031eddc08d5.78601696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC080C38-F1C8-45EA-82AE-C0E5143A0A09</gtr:id><gtr:title>a-Synuclein mutations cluster around a putative protein loop.</gtr:title><gtr:parentPublicationTitle>Neuroscience letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/697536feebefd233256c0907479ff552"><gtr:id>697536feebefd233256c0907479ff552</gtr:id><gtr:otherNames>Kara E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0304-3940</gtr:issn><gtr:outcomeId>pm_16517_27_23669636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DA1285D-9E04-4D79-B21E-99EAE2F8E808</gtr:id><gtr:title>Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16517_27_22815559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44C7B081-7F60-4B57-A97C-6159A48F3C82</gtr:id><gtr:title>Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c223010d32ca9d2c262c457376f4ec2"><gtr:id>0c223010d32ca9d2c262c457376f4ec2</gtr:id><gtr:otherNames>Dunn L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_24300239</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26FAC229-7CCB-4CEE-A680-7EA2AC570246</gtr:id><gtr:title>Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA).</gtr:title><gtr:parentPublicationTitle>Current neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94931914f1fe9277fbe2bc12b6a4c8a0"><gtr:id>94931914f1fe9277fbe2bc12b6a4c8a0</gtr:id><gtr:otherNames>Schneider SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1570-159X</gtr:issn><gtr:outcomeId>pm_16517_27_23814539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A126D991-FCD2-4C7A-A2C5-468D96955F73</gtr:id><gtr:title>Pantothenate kinase-associated neurodegeneration is not a synucleinopathy.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c5c2253c4ba1d1ab5829aa152019a46"><gtr:id>7c5c2253c4ba1d1ab5829aa152019a46</gtr:id><gtr:otherNames>Li A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>pm_16517_27_22416811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AC91573-FE7B-4393-B3F9-C747821B9854</gtr:id><gtr:title>Insights into TREM2 biology by network analysis of human brain gene expression data.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05229e5e9f0a501fa7e63a396d570040"><gtr:id>05229e5e9f0a501fa7e63a396d570040</gtr:id><gtr:otherNames>Forabosco P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_23855984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F5DC19F-D2F8-40D9-8C5E-3E61DF7173A2</gtr:id><gtr:title>A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59ea7d2c64ff79f8317739eecd92c89d"><gtr:id>59ea7d2c64ff79f8317739eecd92c89d</gtr:id><gtr:otherNames>Karran E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>56e0323385d733.51608954</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>584147B0-CF06-4DC3-B04F-9E799E9E5CF8</gtr:id><gtr:title>Primary and secondary dystonic syndromes: an update.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80bdbfdd0b1d93ff7f53295d25d425e7"><gtr:id>80bdbfdd0b1d93ff7f53295d25d425e7</gtr:id><gtr:otherNames>Charlesworth G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>pm_16517_27_23757263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74F2FEE6-B34B-42A4-9170-8DF8D6F8B9E2</gtr:id><gtr:title>How could Parkin-mediated ubiquitination of mitofusin promote mitophagy?</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/988f5379d9b93f0a80f8e96af06ef35f"><gtr:id>988f5379d9b93f0a80f8e96af06ef35f</gtr:id><gtr:otherNames>Ziviani E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>pm_16517_27_20484985</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEDA8A7D-5ABE-4026-B0CF-CF2506AEFEA9</gtr:id><gtr:title>Functional (psychogenic) movement disorders: merging mind and brain.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3948ace15600c52fdd5dc8b73b1e55c"><gtr:id>f3948ace15600c52fdd5dc8b73b1e55c</gtr:id><gtr:otherNames>Edwards MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_16517_27_22341033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA07C5F9-AF69-471F-AE77-17B351C5A330</gtr:id><gtr:title>Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9daf1044ffaa78c220fa83b15b9c753"><gtr:id>b9daf1044ffaa78c220fa83b15b9c753</gtr:id><gtr:otherNames>Ferrari R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>54b7eff420b631.03216285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87E27BC6-49F1-4489-A390-857F9D7DCD42</gtr:id><gtr:title>The WNK-regulated SPAK/OSR1 kinases directly phosphorylate and inhibit the K+-Cl- co-transporters.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6176b52afb3806221e65faf996e7ef62"><gtr:id>6176b52afb3806221e65faf996e7ef62</gtr:id><gtr:otherNames>de Los Heros P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56e032375773b0.94429850</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28BC771E-8C6D-44FD-9F46-6020138B8196</gtr:id><gtr:title>Madras motor neuron disease (MMND) is distinct from the riboflavin transporter genetic defects that cause Brown-Vialetto-Van Laere syndrome.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a2993fc77ed42ab56e9055e6aaaf4cc"><gtr:id>2a2993fc77ed42ab56e9055e6aaaf4cc</gtr:id><gtr:otherNames>Nalini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>pm_16517_27_24139842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B00A9F6-C088-4E12-AAE3-20BB26897FD9</gtr:id><gtr:title>PINK1 cleavage at position A103 by the mitochondrial protease PARL.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56e031ece446a1.82470447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>966E1192-5A69-4F63-9169-F70A36F346CF</gtr:id><gtr:title>Nonsense mutation in PRNP associated with clinical Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d14505f1916bc463c5643c1c28d8"><gtr:id>56b2d14505f1916bc463c5643c1c28d8</gtr:id><gtr:otherNames>Guerreiro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>54b7eff46b6676.68607551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>626C0199-B612-4739-9B4E-56321BFCB4C4</gtr:id><gtr:title>The distinct movement disorder in anti-NMDA receptor encephalitis may be related to Status Dissociatus: a hypothesis.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22700398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C67F509E-E9FA-43E9-B063-FE91CE675E7C</gtr:id><gtr:title>Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/462c9fdb2463f8600afeb02ea9651391"><gtr:id>462c9fdb2463f8600afeb02ea9651391</gtr:id><gtr:otherNames>Yao C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16517_27_23065705</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8D1AF95-2BE2-442F-BEC1-D4879D7F02CA</gtr:id><gtr:title>Nrf2 regulates ROS production by mitochondria and NADPH oxidase.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/004697617100ed65fc00a8b344df86cc"><gtr:id>004697617100ed65fc00a8b344df86cc</gtr:id><gtr:otherNames>Kovac S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>56e03239dc3c85.03015468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53DF8BF9-B529-4B97-8EAA-EC59A6E2511A</gtr:id><gtr:title>THAP1 mutations in a Greek primary blepharospasm series.</gtr:title><gtr:parentPublicationTitle>Parkinsonism &amp; related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7683c72a503be0311ba813667c505f75"><gtr:id>7683c72a503be0311ba813667c505f75</gtr:id><gtr:otherNames>Xiromerisiou G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1353-8020</gtr:issn><gtr:outcomeId>pm_16517_27_23036512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B68C0B5A-3583-403D-8CFC-E4F9C42E4808</gtr:id><gtr:title>Botulinum toxin injections reduce associative plasticity in patients with primary dystonia.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a710ca1824f44073ef7bb8d23ab87321"><gtr:id>a710ca1824f44073ef7bb8d23ab87321</gtr:id><gtr:otherNames>Kojovic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_21469207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC79B8F3-8D3F-48FF-8CED-9BFA14737A6C</gtr:id><gtr:title>Naringenin inhibits the growth of Dictyostelium and MDCK-derived cysts in a TRPP2 (polycystin-2)-dependent manner.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b17832ab6d6038b2bc30fd2d2f2ff047"><gtr:id>b17832ab6d6038b2bc30fd2d2f2ff047</gtr:id><gtr:otherNames>Waheed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>56e03232408299.81595075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ED15FE9-248C-4BF6-8C13-CF3D1FDBE66E</gtr:id><gtr:title>Mutations in HPCA cause autosomal-recessive primary isolated dystonia.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80bdbfdd0b1d93ff7f53295d25d425e7"><gtr:id>80bdbfdd0b1d93ff7f53295d25d425e7</gtr:id><gtr:otherNames>Charlesworth G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5697b16b71ae49.24371528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A12E0E17-7E9E-48E9-A70F-EF67AB16E062</gtr:id><gtr:title>AF-6 is a positive modulator of the PINK1/parkin pathway and is deficient in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c237bed3b349914262dd273e6fedf24a"><gtr:id>c237bed3b349914262dd273e6fedf24a</gtr:id><gtr:otherNames>Haskin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16517_27_23393160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01010993-DD41-4792-A2BA-F6E2C78510FC</gtr:id><gtr:title>Deciphering the function of leucine-rich repeat kinase 2 and targeting its dysfunction in disease.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43c07010bfe3a3446b64256aded46ad8"><gtr:id>43c07010bfe3a3446b64256aded46ad8</gtr:id><gtr:otherNames>Lewis PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_16517_27_22988861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64CC5BB1-94A9-487C-888B-37287D1B7AB7</gtr:id><gtr:title>A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ed0f28b35d5e4240d5af6d917b092bf"><gtr:id>8ed0f28b35d5e4240d5af6d917b092bf</gtr:id><gtr:otherNames>Mencacci NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>56decb810be899.62875922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91D00C8B-8D86-4B16-8916-D44DE89065A4</gtr:id><gtr:title>Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeab5dcf8187a67e2a1d2237a3100588"><gtr:id>aeab5dcf8187a67e2a1d2237a3100588</gtr:id><gtr:otherNames>Tsika E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>54b7eff3ea4088.38454044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94C617A9-D7B6-4EE5-983C-8526CFC6C721</gtr:id><gtr:title>Cell metabolism affects selective vulnerability in PINK1-associated Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/521f8366c59ab87c062c9c49a518c4b8"><gtr:id>521f8366c59ab87c062c9c49a518c4b8</gtr:id><gtr:otherNames>Yao Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>pm_16517_27_22223879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E6EEE00-0BE3-4532-BBBF-0A66A9DB5E9E</gtr:id><gtr:title>A two-stage meta-analysis identifies several new loci for Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21954146dfa6bdef021f2fa27d03fd93"><gtr:id>21954146dfa6bdef021f2fa27d03fd93</gtr:id><gtr:otherNames>International Parkinson's Disease Genomics Consortium (IPDGC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>Hgz3pqm7wc2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0299365-DFB8-47B3-BC4E-C398A09F65D1</gtr:id><gtr:title>Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da3d30139af2f7d5f115630714930c3a"><gtr:id>da3d30139af2f7d5f115630714930c3a</gtr:id><gtr:otherNames>Kinghorn KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56e032e77a40d0.30680832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B459ABD4-7E92-4F84-B2C2-29BC4984D6BD</gtr:id><gtr:title>Influence of microRNA deregulation on chaperone-mediated autophagy and a-synuclein pathology in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7322e4d45d8d897e3ce8b1d90bde79b"><gtr:id>f7322e4d45d8d897e3ce8b1d90bde79b</gtr:id><gtr:otherNames>Alvarez-Erviti L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_16517_27_23492776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41D61714-DDF6-4E53-98BF-341E23CA94A2</gtr:id><gtr:title>Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc6f5d980b9f26a631bb27b333a684ff"><gtr:id>fc6f5d980b9f26a631bb27b333a684ff</gtr:id><gtr:otherNames>Sassi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56e03233e6d658.05872933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AE37C32-7D2F-438D-B088-22FEC19A0D17</gtr:id><gtr:title>MASL1: a neglected ROCO protein.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93fc073fbe54ba9ea4dd041091d5dffa"><gtr:id>93fc073fbe54ba9ea4dd041091d5dffa</gtr:id><gtr:otherNames>Dihanich S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_16517_27_22988871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E85F5343-CD4F-4D4A-AAC9-DADEE8EE9F51</gtr:id><gtr:title>Nrf2 affects the efficiency of mitochondrial fatty acid oxidation.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c57b88710ec55c1fd773937122ad03ee"><gtr:id>c57b88710ec55c1fd773937122ad03ee</gtr:id><gtr:otherNames>Ludtmann MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56e032328b8764.96879113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>237613A6-F16A-4DE1-94E3-6FCE254E0909</gtr:id><gtr:title>Bioenergetic consequences of PINK1 mutations in Parkinson disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2312f559dcfb3144a0b4c3c4b307152"><gtr:id>a2312f559dcfb3144a0b4c3c4b307152</gtr:id><gtr:otherNames>Abramov AY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16517_27_22043288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B11C1EC0-4CC2-44C6-BB76-9C711150BABE</gtr:id><gtr:title>Parkinson's disease and cancer: two wars, one front.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>56e031ed1482f5.04246647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77A4B3FB-6A96-4051-886E-A185D4931A01</gtr:id><gtr:title>Characterization of PLA2G6 as a locus for dystonia-parkinsonism.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e7ca46dd73dfb1e927975f9d7e0b57"><gtr:id>e7e7ca46dd73dfb1e927975f9d7e0b57</gtr:id><gtr:otherNames>Paisan-Ruiz C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>2A0B4F0B9D2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>955F78D6-5299-4BF8-A638-5D4E56580C21</gtr:id><gtr:title>Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d14505f1916bc463c5643c1c28d8"><gtr:id>56b2d14505f1916bc463c5643c1c28d8</gtr:id><gtr:otherNames>Guerreiro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>54b7eff37eab78.74774559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7305C47F-9545-4F7A-8654-84CF24E190C3</gtr:id><gtr:title>The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b45f75b0c7637f862f1b025d4b726505"><gtr:id>b45f75b0c7637f862f1b025d4b726505</gtr:id><gtr:otherNames>Klebe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_16517_27_23408064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>911041E7-A14D-4A2E-BD53-D712CE471860</gtr:id><gtr:title>Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc6be3b3e5ee776d6c6cd87eccb0be6f"><gtr:id>cc6be3b3e5ee776d6c6cd87eccb0be6f</gtr:id><gtr:otherNames>Mok KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>5889d4fc200573.20473026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAE04233-AFE5-415E-97F2-70432C830277</gtr:id><gtr:title>Structural characterization of toxic oligomers that are kinetically trapped during a-synuclein fibril formation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57638f19b8724d9d700f65c0a31ff018"><gtr:id>57638f19b8724d9d700f65c0a31ff018</gtr:id><gtr:otherNames>Chen SW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56e0323a3a1ac4.77445623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E604257-B5AB-4793-8B1B-0A2D4DC16785</gtr:id><gtr:title>Somatic alpha-synuclein mutations in Parkinson's disease: hypothesis and preliminary data.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad6d814d95a541c7e3a165cbafd92058"><gtr:id>ad6d814d95a541c7e3a165cbafd92058</gtr:id><gtr:otherNames>Proukakis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_23674490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>982314B3-DCE8-43F9-8BEB-F0FCA61AB012</gtr:id><gtr:title>Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7683c72a503be0311ba813667c505f75"><gtr:id>7683c72a503be0311ba813667c505f75</gtr:id><gtr:otherNames>Xiromerisiou G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22488887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A92111E-9C0D-4AB3-A36E-17C0428CB65C</gtr:id><gtr:title>Genetics of Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d14505f1916bc463c5643c1c28d8"><gtr:id>56b2d14505f1916bc463c5643c1c28d8</gtr:id><gtr:otherNames>Guerreiro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1878-7479</gtr:issn><gtr:outcomeId>56e032361a05a8.94021642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8B02242-3928-487E-B642-D657069E3F5F</gtr:id><gtr:title>Clinical prodromes of neurodegeneration in Anderson-Fabry disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/746e2123e85072ed2c287ccb66d9bee2"><gtr:id>746e2123e85072ed2c287ccb66d9bee2</gtr:id><gtr:otherNames>L?hle M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56e03236355bd0.95764673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A0D9129-1DF1-4B3A-9611-09864A22BC4B</gtr:id><gtr:title>Lipid peroxidation is essential for a-synuclein-induced cell death.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8fbb8ccee913c0ad555ab7ec713c5fdd"><gtr:id>8fbb8ccee913c0ad555ab7ec713c5fdd</gtr:id><gtr:otherNames>Angelova PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>56e0323a1946a1.87188109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>484A92A0-B232-4580-A504-2C7E31F0D84C</gtr:id><gtr:title>Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c24855ecb6f14958c378c4a4b3352d2f"><gtr:id>c24855ecb6f14958c378c4a4b3352d2f</gtr:id><gtr:otherNames>Tufi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>54b7eff2a0ae43.37349060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC0E39FF-91C2-4BE9-9AE7-B1C7C2C02201</gtr:id><gtr:title>Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis.</gtr:title><gtr:parentPublicationTitle>Journal of Parkinson's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc3d325cdc9f5b30d594bd43639eab9f"><gtr:id>cc3d325cdc9f5b30d594bd43639eab9f</gtr:id><gtr:otherNames>Jenner P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1877-7171</gtr:issn><gtr:outcomeId>pm_16517_27_23938306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>100EE7B0-C6EB-485C-882C-929B84051714</gtr:id><gtr:title>Direct mobilisation of lysosomal Ca2+ triggers complex Ca2+ signals.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1b4c23834e249e3af880439c63aedb9"><gtr:id>b1b4c23834e249e3af880439c63aedb9</gtr:id><gtr:otherNames>Kilpatrick BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>54b7eff14a3640.56268183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3E89CCC-C671-4DA5-B882-BB8090406300</gtr:id><gtr:title>Glucosylceramidase degradation in fibroblasts carrying bi-allelic Parkin mutations.</gtr:title><gtr:parentPublicationTitle>Molecular genetics and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1096-7192</gtr:issn><gtr:outcomeId>pm_16517_27_23803291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD0684EA-1583-4F4B-8BB2-F02264BAA51B</gtr:id><gtr:title>Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration.</gtr:title><gtr:parentPublicationTitle>Biology open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c12f39f0c4d126b0ff8f01c4a69a02c4"><gtr:id>c12f39f0c4d126b0ff8f01c4a69a02c4</gtr:id><gtr:otherNames>Holmstr?m KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2046-6390</gtr:issn><gtr:outcomeId>pm_16517_27_23951401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37A46900-98EA-4821-B782-46F9DC91D60A</gtr:id><gtr:title>A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf8b293c57e2abbe75629b0924e21ef0"><gtr:id>cf8b293c57e2abbe75629b0924e21ef0</gtr:id><gtr:otherNames>Nalls MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>pm_16517_27_23588557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45F331D0-30B6-48B9-A9F9-75DD8D420AA3</gtr:id><gtr:title>No pathogenic GNAL mutations in 192 sporadic and familial cases of cervical dystonia.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80bdbfdd0b1d93ff7f53295d25d425e7"><gtr:id>80bdbfdd0b1d93ff7f53295d25d425e7</gtr:id><gtr:otherNames>Charlesworth G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>5464b8c584d726.32412659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0804F132-54C3-44B6-8754-C890223799F0</gtr:id><gtr:title>Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistribution.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bc79c6d1bd646b80a6e83cb1ed16ead"><gtr:id>8bc79c6d1bd646b80a6e83cb1ed16ead</gtr:id><gtr:otherNames>Mamais A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56e0323346f556.26336865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE150CD8-AB79-4955-A6ED-76149991C642</gtr:id><gtr:title>ALS2 mutations: juvenile amyotrophic lateral sclerosis and generalized dystonia.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bb76623ba9100a6a132a4d8578ef49e"><gtr:id>8bb76623ba9100a6a132a4d8578ef49e</gtr:id><gtr:otherNames>Sheerin UM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56e031edbbcc75.31887189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>393C8B6F-156A-4DAE-B871-0C888A6ADDF9</gtr:id><gtr:title>Screening for VPS35 mutations in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bb76623ba9100a6a132a4d8578ef49e"><gtr:id>8bb76623ba9100a6a132a4d8578ef49e</gtr:id><gtr:otherNames>Sheerin UM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_22154191</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55C9DAD3-E9AF-4C70-B7DC-6DD1214A6E74</gtr:id><gtr:title>Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c16a5c6bd1f19af17be6a4220f9c252"><gtr:id>3c16a5c6bd1f19af17be6a4220f9c252</gtr:id><gtr:otherNames>Teo JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22865512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3171BC6B-1951-4ED4-B747-7601E05DFFA7</gtr:id><gtr:title>Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_16517_27_22366792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E46EBE8-8F15-41A2-AA74-390B1C9AD028</gtr:id><gtr:title>Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation.</gtr:title><gtr:parentPublicationTitle>Molecular neurodegeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cf5553107e55c233b68c1efaf1db243"><gtr:id>8cf5553107e55c233b68c1efaf1db243</gtr:id><gtr:otherNames>Kiely AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1750-1326</gtr:issn><gtr:outcomeId>56e032e7d66c78.12332120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CBB8B4F-A553-4F40-B53E-69C5B309DB9F</gtr:id><gtr:title>Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9ff70460a8a25a64715383958cc1a82"><gtr:id>a9ff70460a8a25a64715383958cc1a82</gtr:id><gtr:otherNames>Majounie E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_16517_27_22406228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B867CEC-85C9-4D25-BAD2-67DAD5D2A98E</gtr:id><gtr:title>Functional reorganization of sensorimotor cortex in early Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a710ca1824f44073ef7bb8d23ab87321"><gtr:id>a710ca1824f44073ef7bb8d23ab87321</gtr:id><gtr:otherNames>Kojovic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16517_27_22517098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9FF193E-E94A-4628-B634-A3D63866A324</gtr:id><gtr:title>Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation.</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical and biomedical analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7aa961200c3ec35595c2f09741f9594e"><gtr:id>7aa961200c3ec35595c2f09741f9594e</gtr:id><gtr:otherNames>Delbroek L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0731-7085</gtr:issn><gtr:outcomeId>pm_16517_27_23313773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C7B984F-D12F-4193-A4D9-E6DFB293F1BC</gtr:id><gtr:title>Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Neuro-degenerative diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d254c4d5cbb597910a10eaad4c470dab"><gtr:id>d254c4d5cbb597910a10eaad4c470dab</gtr:id><gtr:otherNames>Cheshire P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1660-2854</gtr:issn><gtr:outcomeId>pm_16517_27_24008922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>650C4375-D4D2-4C5C-9DED-9E03C10AB231</gtr:id><gtr:title>Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/609865d4dd5b805590a0ed599a30249b"><gtr:id>609865d4dd5b805590a0ed599a30249b</gtr:id><gtr:otherNames>Bras J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56e0323312df22.08121639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF58B1D9-C067-4ACE-B9F8-8A95E5B4EF4C</gtr:id><gtr:title>Kinase and channel activity of TRPM6 are co-ordinated by a dimerization motif and pocket interaction.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/352ea8f4bb6fc18cf40ce73518149bf6"><gtr:id>352ea8f4bb6fc18cf40ce73518149bf6</gtr:id><gtr:otherNames>van der Wijst J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56e032382ae932.19558779</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48F5F1B8-5B44-46F3-A06F-D4D31346946C</gtr:id><gtr:title>Cooperative genome-wide analysis shows increased homozygosity in early onset Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73f2f0764dd1bcc79b805b94497f0c43"><gtr:id>73f2f0764dd1bcc79b805b94497f0c43</gtr:id><gtr:otherNames>Sim?n-S?nchez J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16517_27_22427796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCA27590-8D0F-405D-8216-7BABBD424FAB</gtr:id><gtr:title>Influence of COMT genotype and affective distractors on the processing of self-generated thought.</gtr:title><gtr:parentPublicationTitle>Social cognitive and affective neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/959c053bb8f24c421b5b1bab95679f2d"><gtr:id>959c053bb8f24c421b5b1bab95679f2d</gtr:id><gtr:otherNames>Kilford EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1749-5016</gtr:issn><gtr:outcomeId>5464b8c6537504.05434508</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6079506A-BF6F-4488-8A5D-8AE7DE0680DD</gtr:id><gtr:title>Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.</gtr:title><gtr:parentPublicationTitle>Expert opinion on therapeutic targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e905395803df499a5bf946eb9e5153e0"><gtr:id>e905395803df499a5bf946eb9e5153e0</gtr:id><gtr:otherNames>Burchell VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1472-8222</gtr:issn><gtr:outcomeId>pm_16517_27_20334487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEFD0BDD-22EC-49F0-B23A-142725CB9E3B</gtr:id><gtr:title>Retinal thinning in Gaucher disease patients and carriers: results of a pilot study.</gtr:title><gtr:parentPublicationTitle>Molecular genetics and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1096-7192</gtr:issn><gtr:outcomeId>pm_16517_27_23639447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D615DA7A-BA3A-47FC-970B-41D143E1B228</gtr:id><gtr:title>Parkinson's disease induced pluripotent stem cells with triplication of the a-synuclein locus.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_16517_27_21863007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52C88F15-FE4C-4E52-9267-EA032C511A40</gtr:id><gtr:title>Ataxia telangiectasia presenting as dopa-responsive cervical dystonia.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80bdbfdd0b1d93ff7f53295d25d425e7"><gtr:id>80bdbfdd0b1d93ff7f53295d25d425e7</gtr:id><gtr:otherNames>Charlesworth G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16517_27_23946315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B8849DC-1D12-40E0-9CF2-DB2CE949FB90</gtr:id><gtr:title>James Parkinson: the man behind the shaking palsy.</gtr:title><gtr:parentPublicationTitle>Journal of Parkinson's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43c07010bfe3a3446b64256aded46ad8"><gtr:id>43c07010bfe3a3446b64256aded46ad8</gtr:id><gtr:otherNames>Lewis PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1877-7171</gtr:issn><gtr:outcomeId>pm_16517_27_23938225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20BA7C53-E0DC-4673-B0D2-D3CC6BE478C4</gtr:id><gtr:title>GTP binding controls complex formation by the human ROCO protein MASL1.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93fc073fbe54ba9ea4dd041091d5dffa"><gtr:id>93fc073fbe54ba9ea4dd041091d5dffa</gtr:id><gtr:otherNames>Dihanich S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>pm_16517_27_24286120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B13E0BB-5A92-490D-BAE1-ADF0F8B25B3C</gtr:id><gtr:title>Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>pm_16517_27_23682122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>166F461A-2FB1-4795-8A78-921C1047259E</gtr:id><gtr:title>Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50945e50d1e1c6d39e7dc9ad7322b46b"><gtr:id>50945e50d1e1c6d39e7dc9ad7322b46b</gtr:id><gtr:otherNames>Ticozzi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56e0323262c4c4.89468264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD3E781F-79AA-4662-9D24-178E7ACB3EF0</gtr:id><gtr:title>Genetic variability in the regulation of gene expression in ten regions of the human brain.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52571622ddf586543c15906e6485b96b"><gtr:id>52571622ddf586543c15906e6485b96b</gtr:id><gtr:otherNames>Ramasamy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>56e032341cbb10.80017911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F5A3038-6066-4818-AE38-00704308625A</gtr:id><gtr:title>NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf8b293c57e2abbe75629b0924e21ef0"><gtr:id>cf8b293c57e2abbe75629b0924e21ef0</gtr:id><gtr:otherNames>Nalls MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56dec9a60e5239.13856461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2778C135-89C3-4D7A-A76C-17177C58A89E</gtr:id><gtr:title>CLN6 disease caused by the same mutation originating in Pakistan has varying pathology.</gtr:title><gtr:parentPublicationTitle>European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d14505f1916bc463c5643c1c28d8"><gtr:id>56b2d14505f1916bc463c5643c1c28d8</gtr:id><gtr:otherNames>Guerreiro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1090-3798</gtr:issn><gtr:outcomeId>pm_16517_27_23735787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE837E55-3062-4FE8-83C6-1FFFA31EBBA9</gtr:id><gtr:title>Assaying the kinase activity of LRRK2 in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of visualized experiments : JoVE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43c07010bfe3a3446b64256aded46ad8"><gtr:id>43c07010bfe3a3446b64256aded46ad8</gtr:id><gtr:otherNames>Lewis PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1940-087X</gtr:issn><gtr:outcomeId>pm_16517_27_22301813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6B86E33-7EC9-479C-B5DC-741E49B2C778</gtr:id><gtr:title>A novel a-synuclein missense mutation in Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad6d814d95a541c7e3a165cbafd92058"><gtr:id>ad6d814d95a541c7e3a165cbafd92058</gtr:id><gtr:otherNames>Proukakis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16517_27_23427326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98C5C412-7B92-44F4-8524-78156D0A3EC4</gtr:id><gtr:title>Psychiatric genetics: are we there yet?</gtr:title><gtr:parentPublicationTitle>JAMA psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cdc37128f45833332c0ee457dd6ee0e"><gtr:id>8cdc37128f45833332c0ee457dd6ee0e</gtr:id><gtr:otherNames>Hardy J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-622X</gtr:issn><gtr:outcomeId>pm_16517_27_23571455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7EC86EA-AC51-4550-B118-201F1D62EA02</gtr:id><gtr:title>Recent developments in biomarkers in Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>pm_16517_27_23823465</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>458968B4-56EC-42C0-9B86-D6DEEED4EE2E</gtr:id><gtr:title>Characterization of TAE684 as a potent LRRK2 kinase inhibitor.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f5ff2310b21823fdc45326aba6a7d2d"><gtr:id>6f5ff2310b21823fdc45326aba6a7d2d</gtr:id><gtr:otherNames>Zhang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_16517_27_22335897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F6B3F30-41AB-4974-B08D-22B7DA530A4F</gtr:id><gtr:title>Chromosome 9 ALS and FTD locus is probably derived from a single founder.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb5ecebb0a95326732850cb51e132dc6"><gtr:id>bb5ecebb0a95326732850cb51e132dc6</gtr:id><gtr:otherNames>Mok K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_21925771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1988266-49A4-49EA-BAB8-CDB4919E6C45</gtr:id><gtr:title>LRRK2: a problem lurking in vesicle trafficking?</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93fc073fbe54ba9ea4dd041091d5dffa"><gtr:id>93fc073fbe54ba9ea4dd041091d5dffa</gtr:id><gtr:otherNames>Dihanich S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pm_16517_27_21734269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B026DA8-2AC7-40F4-9D85-E3922070CDE5</gtr:id><gtr:title>C9ORF72 expansions, parkinsonism, and Parkinson disease: a clinicopathologic study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16517_27_23884045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E760AC6-32D0-4E59-AE9A-5D915428BA20</gtr:id><gtr:title>Screening of DUB activity and specificity by MALDI-TOF mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f54c2ab1237f6ddaf41008f895f52a"><gtr:id>35f54c2ab1237f6ddaf41008f895f52a</gtr:id><gtr:otherNames>Ritorto MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56e0323656fab2.58158691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFBB00EC-2714-4EBA-A233-7F13625F447B</gtr:id><gtr:title>Complex I: inhibitors, inhibition and neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>pm_16517_27_20362572</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>026E62D9-3D52-4486-8BA2-1218DE340CED</gtr:id><gtr:title>Hereditary leukoencephalopathy with axonal spheroids: a spectrum of phenotypes from CNS vasculitis to parkinsonism in an adult onset leukodystrophy series.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6867986db8e51578e846cfba3cd72c66"><gtr:id>6867986db8e51578e846cfba3cd72c66</gtr:id><gtr:otherNames>Lynch DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56e032e7ade211.13544830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9894A35B-CDBD-40AF-932D-C1422CF83724</gtr:id><gtr:title>Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba74b5c3165aaf757c2462f94ee40153"><gtr:id>ba74b5c3165aaf757c2462f94ee40153</gtr:id><gtr:otherNames>LeishGEN Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_16517_27_23291585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>299A8408-FF4F-4A5B-AE33-64CE8B920173</gtr:id><gtr:title>Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac12dfa46c116740844c796a1d6eae70"><gtr:id>ac12dfa46c116740844c796a1d6eae70</gtr:id><gtr:otherNames>Kazlauskaite A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>54b7eff2e39d37.01221216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB0C72EE-7F20-40F0-9EE7-23F775CFD914</gtr:id><gtr:title>PINK1 deficiency in ?-cells increases basal insulin secretion and improves glucose tolerance in mice.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>5464b7e2bd3084.99481426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53BD138F-F08F-4341-A1B1-B8831FECEE41</gtr:id><gtr:title>Ability to cycle despite severe freezing of gait in atypical parkinsonism in Fahr's syndrome.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_21626563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDFBA384-24D0-4E11-8F4A-0AABB32B1BDF</gtr:id><gtr:title>Parkin disease and the Lewy body conundrum.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f07a33be90f6f19bd438059328a9dbb8"><gtr:id>f07a33be90f6f19bd438059328a9dbb8</gtr:id><gtr:otherNames>Doherty KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_23653422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA5116E3-FBBF-48F6-9FF0-11896F798997</gtr:id><gtr:title>Rare individual amyloid-? oligomers act on astrocytes to initiate neuronal damage.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5b88038745dc424d8b278b805ce7f1e"><gtr:id>d5b88038745dc424d8b278b805ce7f1e</gtr:id><gtr:otherNames>Narayan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>5464b8c6037e96.78963369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCA6EA3B-D07C-41FE-96C7-53AD5168B47A</gtr:id><gtr:title>Investigation of LKB1 Ser431 phosphorylation and Cys433 farnesylation using mouse knockin analysis reveals an unexpected role of prenylation in regulating AMPK activity.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f7ab912e35c4538875b97b9e60ca106"><gtr:id>2f7ab912e35c4538875b97b9e60ca106</gtr:id><gtr:otherNames>Houde VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56e032373108c0.65203812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F4E6F40-5D58-4D13-B5A4-38C887A9D90D</gtr:id><gtr:title>Glucocorticoids reduce intracellular calcium concentration and protects neurons against glutamate toxicity.</gtr:title><gtr:parentPublicationTitle>Cell calcium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/420315f0a8657635939cc9a317e98163"><gtr:id>420315f0a8657635939cc9a317e98163</gtr:id><gtr:otherNames>Suwanjang W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0143-4160</gtr:issn><gtr:outcomeId>pm_16517_27_23340218</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>823A90B7-745D-44B0-91F7-368005A14AEF</gtr:id><gtr:title>The blink reflex recovery cycle differs between essential and presumed psychogenic blepharospasm.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/933c853b6f0a20d8ccf3cf131cf4bc87"><gtr:id>933c853b6f0a20d8ccf3cf131cf4bc87</gtr:id><gtr:otherNames>Schwingenschuh P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16517_27_21321334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9E94875-1587-4905-B3CB-DA90A1FFCBDD</gtr:id><gtr:title>Mitochondrial diseases.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_16517_27_22482939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAB7A12A-0776-4E5E-9B36-6418C13559BC</gtr:id><gtr:title>Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fc9b26a4f240104f4f5378597d75aff"><gtr:id>0fc9b26a4f240104f4f5378597d75aff</gtr:id><gtr:otherNames>Trabzuni D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16517_27_23967090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6714CD23-8C9D-4701-8D9B-A0BBE2EC6C99</gtr:id><gtr:title>Modeling pathogenic mutations of human twinkle in Drosophila suggests an apoptosis role in response to mitochondrial defects.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52e6c9ccfef4a17724c3d4dfdd0c70a5"><gtr:id>52e6c9ccfef4a17724c3d4dfdd0c70a5</gtr:id><gtr:otherNames>Sanchez-Martinez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e03238927916.04514081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8FCA1CA-D9D3-4FE8-9BAB-8C9C0CC6745C</gtr:id><gtr:title>A 6.4 Mb duplication of the a-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/697536feebefd233256c0907479ff552"><gtr:id>697536feebefd233256c0907479ff552</gtr:id><gtr:otherNames>Kara E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>54b7eff0f049b0.69350115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7E03030-9EB6-4C63-B918-3F42D9C70C2B</gtr:id><gtr:title>TRAP1 rescues PINK1 loss-of-function phenotypes.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/917fedf7d4ac4a5d4fbb9db6070723d7"><gtr:id>917fedf7d4ac4a5d4fbb9db6070723d7</gtr:id><gtr:otherNames>Zhang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16517_27_23525905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67B2FE00-7E1D-4D35-93E2-DA920DB06169</gtr:id><gtr:title>Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a124d1eb2194aabd08d9c85e61a281e8"><gtr:id>a124d1eb2194aabd08d9c85e61a281e8</gtr:id><gtr:otherNames>Compta Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_16517_27_21596773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C28F4CA-3109-48F3-852E-47FFD7F6B6A0</gtr:id><gtr:title>Direct observation of the interconversion of normal and toxic forms of a-synuclein.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85ce1c4f89fb58daed7d5111bbbf791e"><gtr:id>85ce1c4f89fb58daed7d5111bbbf791e</gtr:id><gtr:otherNames>Cremades N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>pm_16517_27_22632969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0C59B4A-172C-453F-B4BC-823A97FA07E5</gtr:id><gtr:title>Novel single base-pair deletion in exon 1 of XK gene leading to McLeod syndrome with chorea, muscle wasting, peripheral neuropathy, acanthocytosis and haemolysis.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f412cc6b7d29c6e9685797bea1d962d2"><gtr:id>f412cc6b7d29c6e9685797bea1d962d2</gtr:id><gtr:otherNames>Wiethoff S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>54b7eff121b7f0.30471286</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>197A9E9A-1E50-495B-9A16-D8F2DB06584C</gtr:id><gtr:title>Genetic analysis in neurology: the next 10 years.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59eee19a2cfbf0e9ad3bd8586d222ca4"><gtr:id>59eee19a2cfbf0e9ad3bd8586d222ca4</gtr:id><gtr:otherNames>Pittman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>pm_16517_27_23571731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C32B2F74-07C7-4875-A7BB-220C0CA650DE</gtr:id><gtr:title>Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.</gtr:title><gtr:parentPublicationTitle>Expert opinion on therapeutic targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e905395803df499a5bf946eb9e5153e0"><gtr:id>e905395803df499a5bf946eb9e5153e0</gtr:id><gtr:otherNames>Burchell VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1472-8222</gtr:issn><gtr:outcomeId>pm_16517_27_20184395</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5244722-A955-4B04-AAB4-5A3276B0FD1E</gtr:id><gtr:title>a-Synuclein and mitochondrial dysfunction in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Molecular neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82cbf26ea46964d30acb33fe49cc0d89"><gtr:id>82cbf26ea46964d30acb33fe49cc0d89</gtr:id><gtr:otherNames>Mullin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-7648</gtr:issn><gtr:outcomeId>pm_16517_27_23361255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AEC860F-8292-4C06-B43A-FC42C0411EE2</gtr:id><gtr:title>Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/609865d4dd5b805590a0ed599a30249b"><gtr:id>609865d4dd5b805590a0ed599a30249b</gtr:id><gtr:otherNames>Bras J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>pm_16517_27_22714018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4769B656-FEBB-4C5E-8D6B-3C372347F809</gtr:id><gtr:title>Identification of Stk25 as a genetic modifier of Tau phosphorylation in Dab1-mutant mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35cbe417cee942c7b31ca05081893007"><gtr:id>35cbe417cee942c7b31ca05081893007</gtr:id><gtr:otherNames>Matsuki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16517_27_22355340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE1A760F-A37D-4992-8B1F-8E6CC509CB9C</gtr:id><gtr:title>SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e296dd12dae090cc5d3853b122648d61"><gtr:id>e296dd12dae090cc5d3853b122648d61</gtr:id><gtr:otherNames>Le Ber I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>54b7eff19b9517.88537399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20E22EA8-9A34-4D62-B822-A253D737C9B8</gtr:id><gtr:title>Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2596d3af9c0ecb02e3af1d191bf271ea"><gtr:id>2596d3af9c0ecb02e3af1d191bf271ea</gtr:id><gtr:otherNames>Gegg ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>pm_16517_27_23034917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5F3BC91-3628-4DE1-B640-D2C28D892BCC</gtr:id><gtr:title>Movement disorders in adult surviving patients with maple syrup urine disease.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8f5d1f0e35e61942ba087c9f0cc052f"><gtr:id>b8f5d1f0e35e61942ba087c9f0cc052f</gtr:id><gtr:otherNames>Carecchio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_21484869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFC78588-D867-4E45-8F93-A8DAEA5740AF</gtr:id><gtr:title>Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/609865d4dd5b805590a0ed599a30249b"><gtr:id>609865d4dd5b805590a0ed599a30249b</gtr:id><gtr:otherNames>Bras J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16517_27_22388936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A847CCF4-2517-494B-8381-4A1B02969FE1</gtr:id><gtr:title>Genomewide association study in cervical dystonia demonstrates possible association with sodium leak channel.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc6be3b3e5ee776d6c6cd87eccb0be6f"><gtr:id>cc6be3b3e5ee776d6c6cd87eccb0be6f</gtr:id><gtr:otherNames>Mok KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_24227479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BD7F722-F28E-49B0-992A-2313F6F11555</gtr:id><gtr:title>Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e8088f2d6e90105cd78b127c6516c9f"><gtr:id>2e8088f2d6e90105cd78b127c6516c9f</gtr:id><gtr:otherNames>Tucci A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_16517_27_24198383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18327164-3215-421D-9DB4-7364DB468907</gtr:id><gtr:title>Gene expression in the Parkinson's disease brain.</gtr:title><gtr:parentPublicationTitle>Brain research bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43c07010bfe3a3446b64256aded46ad8"><gtr:id>43c07010bfe3a3446b64256aded46ad8</gtr:id><gtr:otherNames>Lewis PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0361-9230</gtr:issn><gtr:outcomeId>pm_16517_27_22173063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E218317F-B723-4743-A9E5-234645AC4421</gtr:id><gtr:title>Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>56e031ed8ad4b5.47517912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC3DCDC1-6445-4F4A-B878-63DF0B4518E7</gtr:id><gtr:title>Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d14505f1916bc463c5643c1c28d8"><gtr:id>56b2d14505f1916bc463c5643c1c28d8</gtr:id><gtr:otherNames>Guerreiro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_23870839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>914815BF-16B7-4C04-9A6C-D432572C4EA3</gtr:id><gtr:title>Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_16517_27_23412333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DE0B66D-E455-404D-B6A7-5796988AC0D5</gtr:id><gtr:title>Cellular processes associated with LRRK2 function and dysfunction.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1daa9c552889120e7495abd55bdca24d"><gtr:id>1daa9c552889120e7495abd55bdca24d</gtr:id><gtr:otherNames>Wallings R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>56e032399c0042.33537831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>271A9108-7128-4882-9456-744DDE034B0E</gtr:id><gtr:title>Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2d0f395414b93ca8e16b698d9d8d12"><gtr:id>1e2d0f395414b93ca8e16b698d9d8d12</gtr:id><gtr:otherNames>International Parkinson Disease Genomics Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>oFgbttL15cK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E837F719-FE23-4446-8E67-474337BA95A5</gtr:id><gtr:title>Exome sequencing expands the mutational spectrum of SPG8 in a family with spasticity responsive to L-DOPA treatment.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9960cd808582e52821f0e586e2ba9176"><gtr:id>9960cd808582e52821f0e586e2ba9176</gtr:id><gtr:otherNames>Bettencourt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_16517_27_23881105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F56EF2C-19D1-4E20-B77F-A5A72D72A8AB</gtr:id><gtr:title>Mitochondrial contribution to Parkinson's disease pathogenesis.</gtr:title><gtr:parentPublicationTitle>Parkinson's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2042-0080</gtr:issn><gtr:outcomeId>pm_16517_27_21687805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C9A7FA1-3C9E-40B7-8154-F3B2AF1920C0</gtr:id><gtr:title>Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage.</gtr:title><gtr:parentPublicationTitle>Neurochemistry international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/362a4a8a0492b5b015a4f25961f7a00e"><gtr:id>362a4a8a0492b5b015a4f25961f7a00e</gtr:id><gtr:otherNames>Cleeter MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-0186</gtr:issn><gtr:outcomeId>pm_16517_27_23099359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B25B429-1611-462E-980C-32E7FF10233A</gtr:id><gtr:title>The phenotypic spectrum of DYT24 due to ANO3 mutations.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>5464b8c5d47bb1.48887599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0718FFB1-1990-42F8-B70D-323E9D5FBB4B</gtr:id><gtr:title>Cellular and molecular mechanisms of mitochondrial function.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical endocrinology &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/475d877ceec760cc4db02f32a29b38b3"><gtr:id>475d877ceec760cc4db02f32a29b38b3</gtr:id><gtr:otherNames>Osellame LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1521-690X</gtr:issn><gtr:outcomeId>pm_16517_27_23168274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC7159CC-0C08-47F6-AE11-AA8F3BD9E51C</gtr:id><gtr:title>G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b16b112accd58f4d33cb340dff3ea1cd"><gtr:id>b16b112accd58f4d33cb340dff3ea1cd</gtr:id><gtr:otherNames>Papkovskaia TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16517_27_22736029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77B168DE-EBBA-45D7-94A8-DF92EE51D368</gtr:id><gtr:title>Dopamine induced neurodegeneration in a PINK1 model of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe26393ce1a826c37d2c03b54270978"><gtr:id>7fe26393ce1a826c37d2c03b54270978</gtr:id><gtr:otherNames>Gandhi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16517_27_22662171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2ACB209-568B-4AA3-9E87-99EC1AD0BE8B</gtr:id><gtr:title>Prolonged seizure activity impairs mitochondrial bioenergetics and induces cell death.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/004697617100ed65fc00a8b344df86cc"><gtr:id>004697617100ed65fc00a8b344df86cc</gtr:id><gtr:otherNames>Kovac S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>pm_16517_27_22328526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF6B12A8-F1C0-4470-AD7E-EBEB90F9B28D</gtr:id><gtr:title>CSF biomarking for diagnosis and treatment assessment in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cdc37128f45833332c0ee457dd6ee0e"><gtr:id>8cdc37128f45833332c0ee457dd6ee0e</gtr:id><gtr:otherNames>Hardy J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>pm_16517_27_22994375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BDB20A9-256A-4912-97D4-45078FDDB6FE</gtr:id><gtr:title>a-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cf5553107e55c233b68c1efaf1db243"><gtr:id>8cf5553107e55c233b68c1efaf1db243</gtr:id><gtr:otherNames>Kiely AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_16517_27_23404372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F96CDA17-AEBB-42F5-96FB-48A0577B95A7</gtr:id><gtr:title>Using Exome Sequencing to Reveal Mutations in TREM2 Presenting as a Frontotemporal Dementia-like Syndrome Without Bone Involvement</gtr:title><gtr:parentPublicationTitle>JAMA Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d14505f1916bc463c5643c1c28d8"><gtr:id>56b2d14505f1916bc463c5643c1c28d8</gtr:id><gtr:otherNames>Guerreiro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56e0315cceb040.54926225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E615781-CA2F-4CC2-AA23-ECF235CF0EA3</gtr:id><gtr:title>Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.</gtr:title><gtr:parentPublicationTitle>Neurochemistry international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3ad2ee68e9ce39203ee5112a40ba5a6"><gtr:id>f3ad2ee68e9ce39203ee5112a40ba5a6</gtr:id><gtr:otherNames>Chau KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0197-0186</gtr:issn><gtr:outcomeId>pm_16517_27_20624440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86586707-50BA-4EC1-B393-2C8BDA79B95C</gtr:id><gtr:title>Missense variant in TREML2 protects against Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc87a350717c41c65e8df353cdc7e915"><gtr:id>cc87a350717c41c65e8df353cdc7e915</gtr:id><gtr:otherNames>Benitez BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>54b7eff1c4b907.41789526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBBD042A-499B-4BFC-93AD-9BF03E5F8D7C</gtr:id><gtr:title>Genetic variability at the PARK16 locus.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e8088f2d6e90105cd78b127c6516c9f"><gtr:id>2e8088f2d6e90105cd78b127c6516c9f</gtr:id><gtr:otherNames>Tucci A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>pm_16517_27_20683486</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE32210F-B402-49FC-8596-B0C107548B0F</gtr:id><gtr:title>Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68966b6645460364adc33cbe348598d0"><gtr:id>68966b6645460364adc33cbe348598d0</gtr:id><gtr:otherNames>Davies P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>pm_16517_27_23560750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51508CBF-15FF-453C-A513-68A1B4645D42</gtr:id><gtr:title>Analysis of Parkinson's disease brain-derived DNA for alpha-synuclein coding somatic mutations.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad6d814d95a541c7e3a165cbafd92058"><gtr:id>ad6d814d95a541c7e3a165cbafd92058</gtr:id><gtr:otherNames>Proukakis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>5464b8c55fc7e0.88963759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1362529-CE19-4101-A774-3C660D379377</gtr:id><gtr:title>Mechanism of oxidative stress in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Oxidative medicine and cellular longevity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe26393ce1a826c37d2c03b54270978"><gtr:id>7fe26393ce1a826c37d2c03b54270978</gtr:id><gtr:otherNames>Gandhi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1942-0994</gtr:issn><gtr:outcomeId>pm_16517_27_22685618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFA4F951-8F85-49DB-90E9-033AEF2B1E58</gtr:id><gtr:title>Dopamine protects neurons against glutamate-induced excitotoxicity.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/180d61f770401728737d58e473f135f8"><gtr:id>180d61f770401728737d58e473f135f8</gtr:id><gtr:otherNames>Vaarmann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_16517_27_23303129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75AF546C-E531-4223-B3EA-078DD68B81BA</gtr:id><gtr:title>Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d855afc0ff9940fd48713e748ce09024"><gtr:id>d855afc0ff9940fd48713e748ce09024</gtr:id><gtr:otherNames>Bago R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56e03237b277d8.76337867</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D509575A-E6E5-4DE7-A4BB-0159535A8326</gtr:id><gtr:title>Molecular and clinical prodrome of Parkinson disease: implications for treatment.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>pm_16517_27_20479780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80422446-B966-4E03-98E5-4425F0039555</gtr:id><gtr:title>Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b818a2a01467b7c05e419a720ffcb8a"><gtr:id>5b818a2a01467b7c05e419a720ffcb8a</gtr:id><gtr:otherNames>Beavan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>56e032392ad9a1.15523285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C842C09C-5CA3-4262-BCC3-BD4BACF4E0F2</gtr:id><gtr:title>PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9b6f09a6640fea0ca88338ba7ed5668"><gtr:id>f9b6f09a6640fea0ca88338ba7ed5668</gtr:id><gtr:otherNames>Gardiner AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16517_27_23077024</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>575FDD5B-1DBF-49D7-B9B1-53649B2123E4</gtr:id><gtr:title>The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0655441ac2b5df5c89c70a05ddc0ab98"><gtr:id>0655441ac2b5df5c89c70a05ddc0ab98</gtr:id><gtr:otherNames>Alessi DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>56e03237d8c721.55686380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92C48088-3ADA-4590-BFF6-2D7F05C488AD</gtr:id><gtr:title>Limb amputations in fixed dystonia: a form of body integrity identity disorder?</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3948ace15600c52fdd5dc8b73b1e55c"><gtr:id>f3948ace15600c52fdd5dc8b73b1e55c</gtr:id><gtr:otherNames>Edwards MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_21484872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30E1D406-5868-4BF7-B014-BB27C591C8DD</gtr:id><gtr:title>Genetic analysis of pathways to Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cdc37128f45833332c0ee457dd6ee0e"><gtr:id>8cdc37128f45833332c0ee457dd6ee0e</gtr:id><gtr:otherNames>Hardy J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_16517_27_20955928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A995343-5C75-4163-BF51-338F2321460D</gtr:id><gtr:title>Challenges to the development of disease-modifying therapies in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>pm_16517_27_21255199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DDE1B55-FE14-4FEA-BE57-50DFFF776872</gtr:id><gtr:title>Inhibition of LRRK2 kinase activity stimulates macroautophagy.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>pm_16517_27_23916833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>507EF956-14DA-4DF8-B3E4-BE4FCC763D48</gtr:id><gtr:title>Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be4c0da55ab01c9f0e6393f9ed6fadce"><gtr:id>be4c0da55ab01c9f0e6393f9ed6fadce</gtr:id><gtr:otherNames>Hammer MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_16517_27_23332917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7FDD49A-6C2C-4260-ADB7-DFD8AE6DA40E</gtr:id><gtr:title>The CACNA1B R1389H variant is not associated with myoclonus-dystonia in a large European multicentric cohort.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ed0f28b35d5e4240d5af6d917b092bf"><gtr:id>8ed0f28b35d5e4240d5af6d917b092bf</gtr:id><gtr:otherNames>Mencacci NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56e0323ad22736.36606979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>283C2F74-34AB-42F6-A3AE-6B7BD093C7AA</gtr:id><gtr:title>Exome sequencing in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Clinical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/388af7ec97f0f04e969c2b8fd3316906"><gtr:id>388af7ec97f0f04e969c2b8fd3316906</gtr:id><gtr:otherNames>Bras JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-9163</gtr:issn><gtr:outcomeId>pm_16517_27_21651510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ECA2A50-1697-4BC0-AAEC-FA28BE01FBED</gtr:id><gtr:title>Lysine 27 ubiquitination of the mitochondrial transport protein Miro is dependent on serine 65 of the Parkin ubiquitin ligase.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af2d5f2e04b285bdff9667c446ba5cae"><gtr:id>af2d5f2e04b285bdff9667c446ba5cae</gtr:id><gtr:otherNames>Birsa N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>54b7eff3a4a656.33104759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80BB373D-3DD4-40F8-8D53-E831C3140C99</gtr:id><gtr:title>Exome sequencing reveals an unexpected genetic cause of disease: NOTCH3 mutation in a Turkish family with Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f54cad0ab0877e543fc660186cd44ff0"><gtr:id>f54cad0ab0877e543fc660186cd44ff0</gtr:id><gtr:otherNames>Guerreiro RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_22153900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4CA9262-0FFF-41E9-AAB3-69CD7955D869</gtr:id><gtr:title>Tremulous cervical dystonia is likely to be familial: clinical characteristics of a large cohort.</gtr:title><gtr:parentPublicationTitle>Parkinsonism &amp; related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65e7392b7dab0adf61a43ce690e8d2b3"><gtr:id>65e7392b7dab0adf61a43ce690e8d2b3</gtr:id><gtr:otherNames>Rubio-Agusti I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1353-8020</gtr:issn><gtr:outcomeId>pm_16517_27_23523105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73CA5BB0-A32D-4909-9152-54601201D577</gtr:id><gtr:title>Migraine with aura as the predominant phenotype in a family with a PRRT2 mutation.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bb76623ba9100a6a132a4d8578ef49e"><gtr:id>8bb76623ba9100a6a132a4d8578ef49e</gtr:id><gtr:otherNames>Sheerin UM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_16517_27_23180180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4127FD2A-22CD-4477-9A4C-13515AB0B5A3</gtr:id><gtr:title>Pramipexole reduces phosphorylation of a-synuclein at serine-129.</gtr:title><gtr:parentPublicationTitle>Journal of molecular neuroscience : MN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3ad2ee68e9ce39203ee5112a40ba5a6"><gtr:id>f3ad2ee68e9ce39203ee5112a40ba5a6</gtr:id><gtr:otherNames>Chau KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0895-8696</gtr:issn><gtr:outcomeId>pm_16517_27_23681749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84A902A7-43F6-41BF-BD4A-E945E38A09C7</gtr:id><gtr:title>The many faces of mitophagy.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/126cf83db76c0cfe067a140df0997fb2"><gtr:id>126cf83db76c0cfe067a140df0997fb2</gtr:id><gtr:otherNames>Ivatt RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>56e03238dd6173.73106339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4757C1F8-D014-4682-974F-54ED57286713</gtr:id><gtr:title>Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0feec0b8e333c66178c42de9682f01dd"><gtr:id>0feec0b8e333c66178c42de9682f01dd</gtr:id><gtr:otherNames>Angeli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_23818421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D1CE5E1-1CA6-46FB-87ED-E63DCF9845A5</gtr:id><gtr:title>Hyposmia and cognitive impairment in Gaucher disease patients and carriers.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22344629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADEB7757-AA6E-4924-B718-0E61F52E1230</gtr:id><gtr:title>Parkinson's disease and a-synuclein expression.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_21887711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8248C41-CABA-4D45-9039-A080BC3085F0</gtr:id><gtr:title>A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11291e7208395859a2f8dbcb14e782d8"><gtr:id>11291e7208395859a2f8dbcb14e782d8</gtr:id><gtr:otherNames>Holmans P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16517_27_23223016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D6E2E1F-2278-46D0-943B-3ED81971E5F6</gtr:id><gtr:title>PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65b17fed4915e03ecad9b5f9436124ae"><gtr:id>65b17fed4915e03ecad9b5f9436124ae</gtr:id><gtr:otherNames>Kondapalli C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>pm_16517_27_22724072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>000FF6EB-E439-4313-B38C-F4A11125B117</gtr:id><gtr:title>Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/503273474c456315c93d79baa7a3978b"><gtr:id>503273474c456315c93d79baa7a3978b</gtr:id><gtr:otherNames>Dzamko N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>pm_16517_27_20659021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1930380E-8497-499C-B5E3-0AD6AF0FB82D</gtr:id><gtr:title>HtrA2 deficiency causes mitochondrial uncoupling through the F1F0-ATP synthase and consequent ATP depletion.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1a768ac0348b89871dc88cb7217499f"><gtr:id>d1a768ac0348b89871dc88cb7217499f</gtr:id><gtr:otherNames>Plun-Favreau H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_16517_27_22739987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5850DCA-DF21-4813-8C0A-8C102D22B817</gtr:id><gtr:title>Analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ff2cda0ff39441e9d379b03cb269851"><gtr:id>3ff2cda0ff39441e9d379b03cb269851</gtr:id><gtr:otherNames>Schottlaender LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56e032343eab44.70331929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0742311-130C-48CA-A0F3-D7F1F1B06467</gtr:id><gtr:title>A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c935c0efe5b22f529721363ec44ed6dd"><gtr:id>c935c0efe5b22f529721363ec44ed6dd</gtr:id><gtr:otherNames>Singleton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16517_27_21875901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F14185CA-493B-4C62-92E9-24523CBA18C0</gtr:id><gtr:title>Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac12dfa46c116740844c796a1d6eae70"><gtr:id>ac12dfa46c116740844c796a1d6eae70</gtr:id><gtr:otherNames>Kazlauskaite A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>56e032370a4bc6.06933098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F187D42E-CC62-4772-A52B-554BE002E930</gtr:id><gtr:title>Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16517_27_21799870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B163FEE-01DA-4452-A9C0-D9738ABBF765</gtr:id><gtr:title>LRRK2 and human disease: a complicated question or a question of complexes?</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43c07010bfe3a3446b64256aded46ad8"><gtr:id>43c07010bfe3a3446b64256aded46ad8</gtr:id><gtr:otherNames>Lewis PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>pm_16517_27_22253261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F4201A9-B8BB-4106-987E-9DCD176233E8</gtr:id><gtr:title>Sensory tricks in primary cervical dystonia depend on visuotactile temporal discrimination.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8f87b29342e8e7f258f4e331f519c07"><gtr:id>b8f87b29342e8e7f258f4e331f519c07</gtr:id><gtr:otherNames>K?gi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_23283764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA2F41C9-B423-4537-9F81-E73D28B42C5A</gtr:id><gtr:title>Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59cd3d0236088d5035e32ff3fc2435ba"><gtr:id>59cd3d0236088d5035e32ff3fc2435ba</gtr:id><gtr:otherNames>Batla A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_23386566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7332B8AB-AD85-4BCE-A7FF-DBFF48DF1A44</gtr:id><gtr:title>TDP-43 pathology in a patient carrying G2019S LRRK2&amp;nbsp;mutation and a novel p.Q124E MAPT.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79c943d719ca6749410f754081f54667"><gtr:id>79c943d719ca6749410f754081f54667</gtr:id><gtr:otherNames>Ling H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_23664753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BACCD519-7064-4AC7-83F3-3F33D9F126E5</gtr:id><gtr:title>Genetic analysis of mitochondrial protein misfolding in Drosophila melanogaster.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8aabebb2da87ea465161268f62325f3"><gtr:id>e8aabebb2da87ea465161268f62325f3</gtr:id><gtr:otherNames>Pimenta de Castro I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>pm_16517_27_22301916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D188F5DB-7C89-475A-8374-7C74D501F2A2</gtr:id><gtr:title>Phosphorylation of HtrA2 by cyclin-dependent kinase-5 is important for mitochondrial function.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1825a11096392cdb4a65efacbb12473"><gtr:id>b1825a11096392cdb4a65efacbb12473</gtr:id><gtr:otherNames>Fitzgerald JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>56e031ed366172.58437701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25A800AD-6AB5-4CA3-A572-3D178D5CAE79</gtr:id><gtr:title>Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22926781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF1C4B48-0370-4826-B54F-97A65BDFC722</gtr:id><gtr:title>Progressive ataxia and palatal tremor associated with dense pontine calcification: A unique case.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_23436739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>779FA5D3-367A-4DA5-BE6F-9D71609A9854</gtr:id><gtr:title>The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e905395803df499a5bf946eb9e5153e0"><gtr:id>e905395803df499a5bf946eb9e5153e0</gtr:id><gtr:otherNames>Burchell VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>pm_16517_27_23933751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D511F80-0BC1-4515-9A6A-FDB2CD59AF97</gtr:id><gtr:title>PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2: Implications for Parkinson disease pathogenesis.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2596d3af9c0ecb02e3af1d191bf271ea"><gtr:id>2596d3af9c0ecb02e3af1d191bf271ea</gtr:id><gtr:otherNames>Gegg ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>pm_16517_27_21139416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35F847A7-DF3E-495C-9A42-87C441012FF0</gtr:id><gtr:title>Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ed0f28b35d5e4240d5af6d917b092bf"><gtr:id>8ed0f28b35d5e4240d5af6d917b092bf</gtr:id><gtr:otherNames>Mencacci NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5464b7e2ec89d4.85211994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CF1AF66-5D0B-4117-BDD1-5792965C5EA1</gtr:id><gtr:title>Novel pathogenic mutations in the glucocerebrosidase locus.</gtr:title><gtr:parentPublicationTitle>Molecular genetics and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f95aa813f473ac4f55c06f44414f70d4"><gtr:id>f95aa813f473ac4f55c06f44414f70d4</gtr:id><gtr:otherNames>Duran R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1096-7192</gtr:issn><gtr:outcomeId>pm_16517_27_22658918</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE03E62C-9A1F-45CB-A957-38E5874C2335</gtr:id><gtr:title>Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ed587de899b30ad5f3dce3fc99e9d0a"><gtr:id>5ed587de899b30ad5f3dce3fc99e9d0a</gtr:id><gtr:otherNames>Keller MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16517_27_22892372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>317F320B-4BF5-42C1-852D-4FF8B47EC265</gtr:id><gtr:title>Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/027db9c3b84b87202a8838ca43705bf5"><gtr:id>027db9c3b84b87202a8838ca43705bf5</gtr:id><gtr:otherNames>Banerjee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56e0323796f3b2.77007212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E3A6EFA-2887-4C03-9F00-293F497675F1</gtr:id><gtr:title>Drosophila models of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Advances in genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d704511977e8e63398b1b0b8bff08467"><gtr:id>d704511977e8e63398b1b0b8bff08467</gtr:id><gtr:otherNames>Whitworth AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0065-2660</gtr:issn><gtr:outcomeId>pm_16517_27_21310293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2E45EDC-1315-4C7D-9EC4-8A9E96A6E04C</gtr:id><gtr:title>Widespread sex differences in gene expression and splicing in the adult human brain.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fc9b26a4f240104f4f5378597d75aff"><gtr:id>0fc9b26a4f240104f4f5378597d75aff</gtr:id><gtr:otherNames>Trabzuni D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>54b7eff3129aa3.83485245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7E74B3B-7444-4BA5-ADF9-3BE2DB3A4477</gtr:id><gtr:title>Roles of mitochondria in human disease.</gtr:title><gtr:parentPublicationTitle>Essays in biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df3b4dffb07770cf05bb699acad8cfc4"><gtr:id>df3b4dffb07770cf05bb699acad8cfc4</gtr:id><gtr:otherNames>Duchen MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0071-1365</gtr:issn><gtr:outcomeId>pm_16517_27_20533904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB6B3976-D4A8-4F81-A3A2-CB5ACE4FF2FB</gtr:id><gtr:title>Insights from cerebellar transcriptomic analysis into the pathogenesis of ataxia.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9960cd808582e52821f0e586e2ba9176"><gtr:id>9960cd808582e52821f0e586e2ba9176</gtr:id><gtr:otherNames>Bettencourt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>56e03233665aa5.49453573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FFCC743-ACC5-429B-AC6F-B8B0021F07F9</gtr:id><gtr:title>Genome-wide RNAi screen identifies the Parkinson disease GWAS risk locus SREBF1 as a regulator of mitophagy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/126cf83db76c0cfe067a140df0997fb2"><gtr:id>126cf83db76c0cfe067a140df0997fb2</gtr:id><gtr:otherNames>Ivatt RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56e0323906d530.06792677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>834BE677-9111-4515-BCAB-D1D4E31218B1</gtr:id><gtr:title>Mutations in ? adducin are associated with inherited cerebral palsy.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f031c0b2f78e03012bc542323de4d08"><gtr:id>1f031c0b2f78e03012bc542323de4d08</gtr:id><gtr:otherNames>Kruer MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>pm_16517_27_23836506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8036DCC0-8A84-4DE3-BA58-1B9D1C3655B7</gtr:id><gtr:title>Parkinson disease: Parkinson disease clinical subtypes and their implications.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cc8cb977e2c5fdf8f260800585282d4"><gtr:id>6cc8cb977e2c5fdf8f260800585282d4</gtr:id><gtr:otherNames>Schapira AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>pm_16517_27_21423265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C4A3978-26E8-4E28-8893-37CF6222C2FC</gtr:id><gtr:title>The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f95aa813f473ac4f55c06f44414f70d4"><gtr:id>f95aa813f473ac4f55c06f44414f70d4</gtr:id><gtr:otherNames>Duran R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_23225227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F743199-225A-429C-A3A5-BC46CCF57552</gtr:id><gtr:title>A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/405062aea31e15048134bff16a4a7b11"><gtr:id>405062aea31e15048134bff16a4a7b11</gtr:id><gtr:otherNames>Renton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>56e0315ca95134.00494599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58751ED0-8F6C-4E80-8732-05CB3F64A428</gtr:id><gtr:title>Psychogenic palatal tremor may be underrecognized: reappraisal of a large series of cases.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22434706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B98F3517-5BCC-423B-B269-AC3CD460F72F</gtr:id><gtr:title>Creation of an open-access, mutation-defined fibroblast resource for neurological disease research.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ca09ebb1473b9780612d7b5d9dafef"><gtr:id>68ca09ebb1473b9780612d7b5d9dafef</gtr:id><gtr:otherNames>Wray S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16517_27_22952635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>764C29AA-470D-4703-8660-F59115DDBD41</gtr:id><gtr:title>Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>pm_16517_27_24211199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF72E69F-9A71-4FB1-9B65-ABB6134FC20C</gtr:id><gtr:title>Web-based assessment of Parkinson's prodromal markers identifies GBA variants.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba827a97c3d3145072b7a8beef79432d"><gtr:id>ba827a97c3d3145072b7a8beef79432d</gtr:id><gtr:otherNames>Noyce AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>56e0323a569679.98990943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96FA5A72-9A56-4403-A517-05BB3F3774F2</gtr:id><gtr:title>Assessment of Parkinson's disease risk loci in Greece.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/697536feebefd233256c0907479ff552"><gtr:id>697536feebefd233256c0907479ff552</gtr:id><gtr:otherNames>Kara E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_24080174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8491861-AE7A-4153-8DC6-97593D644F6B</gtr:id><gtr:title>No evidence for substrate accumulation in Parkinson brains with GBA mutations.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2596d3af9c0ecb02e3af1d191bf271ea"><gtr:id>2596d3af9c0ecb02e3af1d191bf271ea</gtr:id><gtr:otherNames>Gegg ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>56e03239c1ab11.77038516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E613892-6A3C-4DF7-8A27-02BEAC160D11</gtr:id><gtr:title>Signalling properties of inorganic polyphosphate in the mammalian brain.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c12f39f0c4d126b0ff8f01c4a69a02c4"><gtr:id>c12f39f0c4d126b0ff8f01c4a69a02c4</gtr:id><gtr:otherNames>Holmstr?m KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_16517_27_23322050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90EB5199-F166-4041-A8D2-BF47B512E984</gtr:id><gtr:title>Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn><gtr:outcomeId>56f003611bf1b7.56108101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFE37745-E009-4CA7-848B-548AFBF73944</gtr:id><gtr:title>Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c71e4a1411fff60038bd9e6b563c927"><gtr:id>8c71e4a1411fff60038bd9e6b563c927</gtr:id><gtr:otherNames>Godena VK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56e03235ce71e0.40921014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B12FC081-1CF4-409F-9F96-1CAE91329C18</gtr:id><gtr:title>Parkin disease: a clinicopathologic entity?</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f07a33be90f6f19bd438059328a9dbb8"><gtr:id>f07a33be90f6f19bd438059328a9dbb8</gtr:id><gtr:otherNames>Doherty KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>pm_16517_27_23459986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>259F439A-A7A0-422B-ABC3-192C14EC8887</gtr:id><gtr:title>Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7322e4d45d8d897e3ce8b1d90bde79b"><gtr:id>f7322e4d45d8d897e3ce8b1d90bde79b</gtr:id><gtr:otherNames>Alvarez-Erviti L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>pm_16517_27_21303699</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5877885-C59A-4C3A-9CF9-E77A9B002D05</gtr:id><gtr:title>LRRK2 and autophagy: a common pathway for disease.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_16517_27_22988880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D7DCC87-7E3D-4769-8A50-05158E9AEC5C</gtr:id><gtr:title>GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0641f8e30fd74b7ffb190976ea059c6"><gtr:id>a0641f8e30fd74b7ffb190976ea059c6</gtr:id><gtr:otherNames>Reith AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_16517_27_22863203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCA95661-2CD3-4D9B-9CDE-D530052533FD</gtr:id><gtr:title>Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8fab38dd5065abc5a928948b76aff2f"><gtr:id>d8fab38dd5065abc5a928948b76aff2f</gtr:id><gtr:otherNames>Pais?n-Ruiz C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_16517_27_20619503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63D0E0E4-D21C-46A2-B245-81C275891877</gtr:id><gtr:title>Molecular mechanisms of PINK1-related neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Current neurology and neuroscience reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d5406f6337b9d82fdb4aa125ace837"><gtr:id>a5d5406f6337b9d82fdb4aa125ace837</gtr:id><gtr:otherNames>Pogson JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1528-4042</gtr:issn><gtr:outcomeId>pm_16517_27_21331528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78E2FC53-1C7B-4E1E-9CA2-49DD864EFE91</gtr:id><gtr:title>Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18049378950e97e3da96e50d647b5c6f"><gtr:id>18049378950e97e3da96e50d647b5c6f</gtr:id><gtr:otherNames>Johnson JO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>54b7eff3c6fd91.32840247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B5026B6-30A4-488D-8169-1D53FD64EE05</gtr:id><gtr:title>Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94931914f1fe9277fbe2bc12b6a4c8a0"><gtr:id>94931914f1fe9277fbe2bc12b6a4c8a0</gtr:id><gtr:otherNames>Schneider SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16517_27_22031173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A96A2491-7A40-4FC6-ADAE-7FC14BFBB292</gtr:id><gtr:title>Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzymein multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis and related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52571622ddf586543c15906e6485b96b"><gtr:id>52571622ddf586543c15906e6485b96b</gtr:id><gtr:otherNames>Ramasamy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2211-0348</gtr:issn><gtr:outcomeId>56e03232cb0907.16911976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2A0F3B0-71CE-4A9A-9D71-E6DB0D2B90D1</gtr:id><gtr:title>Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease.</gtr:title><gtr:parentPublicationTitle>Current genetic medicine reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d14505f1916bc463c5643c1c28d8"><gtr:id>56b2d14505f1916bc463c5643c1c28d8</gtr:id><gtr:otherNames>Guerreiro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-4876</gtr:issn><gtr:outcomeId>56e03235eb3fb9.44359717</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8363AE12-E2E8-4EEA-BB28-716955F21FB9</gtr:id><gtr:title>A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccc5b5762113644a4bc53ab2a81094d8"><gtr:id>ccc5b5762113644a4bc53ab2a81094d8</gtr:id><gtr:otherNames>Magdalinou NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56e0323a767a92.58040201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CC64F9E-1C2B-453F-872B-38D24C7756B6</gtr:id><gtr:title>Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f05a4b2f273531c9bc3b22c0ba04d0a7"><gtr:id>f05a4b2f273531c9bc3b22c0ba04d0a7</gtr:id><gtr:otherNames>G?mez-S?nchez R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>pm_16517_27_24184327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6DA5A4D-614E-480A-A930-C30DAA842762</gtr:id><gtr:title>Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb527c8f47b11cfd2bb90849f52723e8"><gtr:id>fb527c8f47b11cfd2bb90849f52723e8</gtr:id><gtr:otherNames>McNeill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16517_27_23935950</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE3C6A2C-1F15-498B-9D09-9D32236F6E0B</gtr:id><gtr:title>Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad3f4aad48683e6e281e5a2c104a3d81"><gtr:id>ad3f4aad48683e6e281e5a2c104a3d81</gtr:id><gtr:otherNames>UK Parkinson's Disease Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>oeYPfsWwcT2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B077C313-C493-48EF-ADC6-46BDA1D26E39</gtr:id><gtr:title>Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Journal of Parkinson's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52a18a5db9cd51743d0b63b9d175aa9c"><gtr:id>52a18a5db9cd51743d0b63b9d175aa9c</gtr:id><gtr:otherNames>Parkkinen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1877-7171</gtr:issn><gtr:outcomeId>pm_16517_27_23939308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D7E820E-D3EA-4BE0-ADA3-6FA3A13423DA</gtr:id><gtr:title>Structural and biochemical characterization of the KLHL3-WNK kinase interaction important in blood pressure regulation.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fd7a99ad803d87bb45f67651daa6a8f"><gtr:id>0fd7a99ad803d87bb45f67651daa6a8f</gtr:id><gtr:otherNames>Schumacher FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56e032380d61c0.51019957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD788CCF-21B2-47C9-94E9-30E191BECFED</gtr:id><gtr:title>Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbc1991b351d7d6e9b3d7c7aff5eb237"><gtr:id>dbc1991b351d7d6e9b3d7c7aff5eb237</gtr:id><gtr:otherNames>deSouza RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>pm_16517_27_23483564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A4ECF43-A679-4575-9BF5-B51DF1AD9C5E</gtr:id><gtr:title>Treatment of focal dystonia.</gtr:title><gtr:parentPublicationTitle>Current treatment options in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59cd3d0236088d5035e32ff3fc2435ba"><gtr:id>59cd3d0236088d5035e32ff3fc2435ba</gtr:id><gtr:otherNames>Batla A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1092-8480</gtr:issn><gtr:outcomeId>pm_16517_27_22415705</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G1000735</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>